<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Cerebral palsy: Treatment of spasticity, dystonia, and associated orthopedic issues</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Cerebral palsy: Treatment of spasticity, dystonia, and associated orthopedic issues</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Cerebral palsy: Treatment of spasticity, dystonia, and associated orthopedic issues</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elizabeth Barkoudah, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Amanda Whitaker, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Marc C Patterson, MD, FRACP</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">William A Phillips, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard P Goddeau, Jr, DO, FAHA</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 17, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H3348419580"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Cerebral palsy (CP) refers to a heterogeneous group of conditions involving permanent motor dysfunction that affects muscle tone, posture, and/or movement. These conditions are due to abnormalities of the developing fetal or infant brain resulting from a variety of non-progressive causes. Although the disorder itself is not neurodegenerative, the clinical expression may change over time as the central nervous system matures. The motor impairment results in limitations in functional abilities and activity, which can vary in severity. Multiple additional symptoms often accompany the primary motor abnormalities, including altered sensation or perception, intellectual disability, communication and behavioral difficulties, seizures, and musculoskeletal complications [<a href="#rid1">1</a>].</p><p>The treatment of spasticity, dystonia, and associated orthopedic issues in patients with CP is discussed here. Other aspects of management and prognosis of CP are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/6176.html" rel="external">"Cerebral palsy: Overview of management and prognosis"</a>.)</p><p>The epidemiology, etiology, prevention, classification, clinical features, evaluation, and diagnosis of CP are also discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6173.html" rel="external">"Cerebral palsy: Epidemiology, etiology, and prevention"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6167.html" rel="external">"Cerebral palsy: Classification and clinical features"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6169.html" rel="external">"Cerebral palsy: Evaluation and diagnosis"</a>.)</p><p></p><p class="headingAnchor" id="H754090483"><span class="h1">FUNCTIONAL EVALUATION AND TREATMENT GOALS</span><span class="headingEndMark"> — </span>Interventions for CP focus on maximizing the child's independence in daily functional activities and reducing the extent of disability. Assessment of the child's functional status guides treatment selection and allows for monitoring of change over time. Standardized tools for assessing motor function include:</p><p class="bulletIndent1"><span class="glyph">●</span>The <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fcanchild.ca%2Fsystem%2Ftenon%2Fassets%2Fattachments%2F000%2F000%2F058%2Foriginal%2FGMFCS-ER_English.pdf&amp;token=12RQvnGHCTgnc7gZ87I2HlNP9O2ajQFxtiGeDFMdU4E5gn0dN1YVxbDmtNhS37KZG1jGYdIycZ2aPCYGxAPgxuxtj1g16dIm2NRmX1kgQzvhq4Ju4xQKTPokQZk6DuSf&amp;TOPIC_ID=118855" target="_blank">Gross Motor Function Classification System</a> (GMFCS)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.macs.nu%2F&amp;token=5yLNPmHjkOhvnhOBCCm6DMZShUOBr6Gls%2BRP0WJX%2Fsg%3D&amp;TOPIC_ID=118855" target="_blank">Manual Ability Classification System</a> (MACS)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fcfcs.us%2F&amp;token=j9UWcFlTVb5IfQxyO4%2BM14vR8ciQfk800A463Fedms0%3D&amp;TOPIC_ID=118855" target="_blank">Communication Function Classification System</a> (CFCS)</p><p></p><p>Additional clinical tools include the Modified Ashworth Scale  (<a class="graphic graphic_table graphicRef93413" href="/z/d/graphic/93413.html" rel="external">table 1</a>), which assesses tone, and the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fnchs%2Fdata%2Ficd%2Ficfoverview_finalforwho10sept.pdf&amp;token=091BzgMihw9v3JR9fveXL3WhAAYr7Emb4CrsjUNhux%2FmQH0wZd8LPgDjYhTHoj3kDtu0FbzVA%2FCC8%2FgezQppagP2r7yi5yDySusvxzC9DUQ%3D&amp;TOPIC_ID=118855" target="_blank">International Classification of Functioning, Disability and Health</a> (ICF), which can be used to conceptualize the impact of CP on different elements of a child's health, function, and participation.</p><p>Evaluating the child's functional status and establishing treatment goals are discussed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/6176.html" rel="external">"Cerebral palsy: Overview of management and prognosis", section on 'Functional evaluation'</a> and  <a class="medical medical_review" href="/z/d/html/6167.html" rel="external">"Cerebral palsy: Classification and clinical features", section on 'Functional classification systems'</a>.)</p><p class="headingAnchor" id="H282863009"><span class="h1">MANAGEMENT OF ALTERED MOTOR FUNCTION</span><span class="headingEndMark"> — </span>By definition, all children with CP have altered motor function to some extent, affecting posture, coordination, and balance. Treatment interventions are typically offered from least to most invasive.</p><p class="headingAnchor" id="H1262870366"><span class="h2">Early intervention</span><span class="headingEndMark"> — </span>Therapeutic interventions should start at the time of the suspected diagnosis of CP to help maximize functional improvement related to neuromuscular plasticity of the developing brain. Referral for physical and occupational as well as other CP-specific therapies includes task-specific modalities and may be tailored to the age of the child [<a href="#rid2">2</a>].</p><p class="headingAnchor" id="H3586321310"><span class="h2">Physical and occupational therapy</span><span class="headingEndMark"> — </span>Physical therapy (PT) is an established part of treatment programs for CP and is an integral and vital part of management. Although its effectiveness in advancing physical function is uncertain, PT has an important role in promoting range of motion, positioning, stamina, and coordination, all of which can directly impact mobility and, with more severe forms of CP, transfers. Occupational therapy (OT) is equally important and focuses on fine motor skill development and improving capacity for self-care or caregiver support of tasks of daily living. As such, targeted activities include skills such as feeding, toileting, dressing, personal hygiene, and fine motor tasks, which are important for school success.</p><p>PT/OT are typically started early and continued by the parents or caregivers at home between sessions [<a href="#rid2">2,3</a>]. Session frequency, length, and duration are based on the child's needs. Services may be rendered at school (as part of an individualized educational plan), in the community, or in both settings. Intensive programs, which may include combinations of occupational, physical, and speech therapy, can be incorporated into the child's standard therapy schedule.</p><p>The efficacy and evidence base varies substantially among different types of therapeutic approaches. The best supported approaches are [<a href="#rid2">2,4,5</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bimanual training for hemiplegic CP</strong> – Trains the child in the use of two hands together through repetitive tasks [<a href="#rid6">6-8</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Constraint-induced movement therapy</strong> – For children with hemiplegic CP, constraint-induced movement therapy (CIMT) promotes improved motor and sensory function of the affected limb by encouraging its use through intermittent restraint of the unaffected limb during therapeutic tasks [<a href="#rid6">6-10</a>]. The method of restraint varies from holding a child's hand to casting, and the length of time in the restraint varies from 1 to 24 hours a day. "Forced use" is a variation of CIMT in which the limb's use is encouraged only by placement of the contralateral restraint; no additional therapeutic tasks are assigned to the affected limb [<a href="#rid11">11-13</a>]. Because the methods and outcomes used varied considerably among these trials, it is unclear which specific CIMT techniques are most useful [<a href="#rid14">14,15</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Context-focused therapy</strong> – Promotes successful task performance by changing the task or environment rather than changing the child's approach. A single randomized trial showed that this was as effective as child-focused therapy, in which there is a focus on remediation of motor impairment through practice of functional activities [<a href="#rid16">16</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Goal-directed/functional training</strong> – Focuses on activities based on goals set by the child, using a motor-learning or task-specific approach [<a href="#rid8">8,17-20</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Occupational therapy after botulinum neurotoxin (BoNT) treatment</strong> – Uses a variety of therapeutic approaches delivered in conjunction with BoNT treatment [<a href="#rid21">21-24</a>]. (See <a class="local">'Botulinum toxin'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Aerobic exercise</strong> – Fitness training incorporating aerobic conditioning may improve both aerobic capacity and gross motor function [<a href="#rid25">25-27</a>]. Exercise programs are only effective in individuals who have sufficient motor skills to permit participation and are beneficial only as long as training continues.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other</strong> – Other approaches supported by at least moderate quality evidence are home programs for improving motor activity performance or self-care [<a href="#rid17">17</a>]. Equine-assisted therapies (eg, hippotherapy) may improve ambulation and gross motor function [<a href="#rid28">28</a>]. </p><p></p><p>Although many of these approaches have been found to be effective in randomized trials and systematic reviews, the quality of the evidence is low to moderate for most, and clinical decisions must be based on individual patient characteristics and available resources [<a href="#rid4">4,29</a>].</p><p>In a comprehensive review, therapeutic approaches that were <strong>not</strong> recommended because the available evidence suggests they are ineffective include passive neurodevelopmental therapy (NDT), sensory integration therapy (SIT), craniosacral therapy, and hip bracing [<a href="#rid2">2,29,30</a>]. NDT is the direct passive handling of limbs by the therapist, with guidance intended to normalize the patterns of movement. It is not recommended because of the availability of more effective alternatives [<a href="#rid2">2,29-32</a>]. Any gains in range of motion that are achieved during an NDT session do not carry over. Better functional gains are achieved with active motor-learning approaches [<a href="#rid30">30,33</a>], and BoNT is more effective than NDT for managing spasticity [<a href="#rid29">29</a>]. Similarly, systematic reviews conclude that SIT is not effective and should be replaced by effective evidence-based alternatives such as those listed above [<a href="#rid2">2,29,34</a>].</p><p>Many other interventions are supported only by very low-quality or inconclusive evidence, precluding a recommendation for or against their use [<a href="#rid29">29</a>]. This includes animal-assisted therapy [<a href="#rid35">35</a>], conductive education [<a href="#rid36">36</a>], taping [<a href="#rid37">37</a>], Feldenkrais therapy [<a href="#rid38">38</a>], hydrotherapy, massage, oral-motor therapy, seating and positioning, stretching, TheraSuits, and whole-body vibration [<a href="#rid29">29</a>].</p><p class="headingAnchor" id="H39639853"><span class="h2">Orthotics and other devices</span><span class="headingEndMark"> — </span>Numerous devices are available to help promote function, mobility, and participation for children with CP. These include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Braces/orthotics</strong> – Many children with CP benefit from bracing to enhance musculoskeletal alignment, promote function, and delay or prevent joint contractures [<a href="#rid39">39,40</a>]. Ankle-foot orthotics are the most frequently used devices, followed by orthotics for the wrist and hand. Orthotics for the knees or hips can also be useful to assist with ambulation or balance. Some braces are intended to be worn with specific activities, such as walking, using a gait trainer, or weight bearing in a stander, while others are intended to be used in sleep to promote joint alignment. Devices that use functional electrical stimulation via foot drop stimulation (eg, Bioness, Walkaide) have been shown to improve gait performance in adult patients with hemiplegia secondary to stroke, and they may be helpful to children with hemiplegic CP [<a href="#rid41">41</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Standers</strong> – As a child grows, functional equipment is often introduced to allow for age appropriate participation and to promote health. For children who are unable to weight bear independently, standers allow for participation in upright activities. At the same time, they promote bone health and can have positive secondary impacts on gastrointestinal motility and respiratory health.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Seating systems</strong> – A variety of seating systems may be used to optimize positioning during activities, from eating meals at home to participating in the classroom. Seating systems may allow for better head positioning, enhance upright posture, or tilt to allow for interventions or rest.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mobility devices</strong> – For the child who is unable to ambulate independently or for long distances, mobility devices are critical. Wheelchairs can be introduced as early as two or three years. Most children who need a wheelchair start with a manual chair that allows another person to push them. Over time, if the child has the cognitive, visual, and motor abilities to steer a chair independently, an electric version may be appropriate and provide the child with more autonomy. There are numerous adaptations that allow a child who might have motor difficulty manipulating a joystick to steer, including knee and head controls. Lightweight adaptive strollers are less cumbersome than wheelchairs and are useful for quick transportation in the community and easier to accommodate in most vehicles.</p><p></p><p>Many specialty centers offer specialized clinics for evaluation of equipment and/or augmentative communication needs. These can be invaluable resources to the primary care clinician in identifying the most appropriate piece of equipment for the child and can also assist the caregivers in navigating the complex insurance regulations that can impact the timing and range of equipment available.</p><p class="headingAnchor" id="H3293303263"><span class="h1">TONE MANAGEMENT</span><span class="headingEndMark"> — </span>Pharmacologic and/or surgical interventions may help to reduce the altered tone associated with CP and improve functioning. Characterizing the nature and severity of the altered tone is necessary to help guide treatment options. Spasticity and dystonia may be more amenable to treatment than weakness or dyscoordination. (See  <a class="medical medical_review" href="/z/d/html/6176.html" rel="external">"Cerebral palsy: Overview of management and prognosis", section on 'Assessment of tone'</a>.)</p><p>When deciding whether to initiate or escalate treatments for altered tone, understanding goals of the child and caregiver are important. Functional considerations include:</p><p class="bulletIndent1"><span class="glyph">●</span>Is the altered tone causing considerable functional impairment?</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Is the altered tone causing chronic pain or discomfort?</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Does the altered tone make caregiving challenging (eg, positioning, hygiene, or dressing)?</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Is the child's sleep disrupted as a consequence of their altered tone?</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>What is the level of concern of the patient and parent or caregiver?</p><p></p><p class="headingAnchor" id="H1548481523"><span class="h2">Spasticity</span></p><p class="headingAnchor" id="H619108116"><span class="h3">General approach</span><span class="headingEndMark"> — </span>There are many options available for the treatment of spasticity for children with CP. Treatments options may vary according to several factors including the child's age, goals for treatment, comorbid conditions, risk of adverse effects from treatment, regional distribution of spasticity, and the response to any prior treatments.</p><p>Physical and/or occupational therapy (PT/OT), position optimization, and orthotic use should be integrated into care for all patients (see <a class="local">'Physical and occupational therapy'</a> above and <a class="local">'Orthotics and other devices'</a> above). The general approach to additional pharmacologic and surgical treatments is as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>For children with generalized spasticity, oral antispasticity drugs are usually the first-line treatment (eg, <a class="drug drug_pediatric" data-topicid="12983" href="/z/d/drug information/12983.html" rel="external">baclofen</a> or benzodiazepines). (See <a class="local">'Oral antispasticity drugs'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For treatment of localized or segmental spasticity, botulinum neurotoxin (BoNT) injections are appropriate. Alcohol block can be used in conjunction with BoNT or as an alternative for patients who do not tolerate or respond to BoNT, but there is less evidence to support its use. (See <a class="local">'Botulinum toxin'</a> below and <a class="local">'Alcohol block'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with spastic diplegia who have mild to moderate motor impairment (Gross Motor Function Classification System [GMFCS] level II or III), no significant weakness, and are cognitively able and motivated to participate in post-surgery rehabilitation, selective dorsal rhizotomy (SDR) may be performed as an alternative to or along with antispasticity therapy to improve gait. (See <a class="local">'Selective dorsal rhizotomy'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For severely affected children (GMFCS level IV or V) who have significant side effects with oral antispasticity drugs or who do not achieve adequate response despite maximal dose, an intrathecal <a class="drug drug_pediatric" data-topicid="12983" href="/z/d/drug information/12983.html" rel="external">baclofen</a> pump may achieve better control of spasticity. SDR is an alternative option for nonambulatory children to address refractory spasticity, provide comfort, and promote participation in activities of daily life [<a href="#rid42">42</a>]. (See <a class="local">'Intrathecal baclofen'</a> below and <a class="local">'Selective dorsal rhizotomy'</a> below.)</p><p></p><p class="headingAnchor" id="H2514948445"><span class="h3">Oral antispasticity drugs</span><span class="headingEndMark"> — </span><a class="drug drug_pediatric" data-topicid="12983" href="/z/d/drug information/12983.html" rel="external">Baclofen</a> and benzodiazepines have been most extensively used and are considered first-line agents to treat spasticity in children with CP [<a href="#rid43">43,44</a>]. Second-line agents include <a class="drug drug_pediatric" data-topicid="13203" href="/z/d/drug information/13203.html" rel="external">dantrolene</a> and <a class="drug drug_pediatric" data-topicid="112669" href="/z/d/drug information/112669.html" rel="external">tizanidine</a>.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Baclofen</strong> – <a class="drug drug_pediatric" data-topicid="12983" href="/z/d/drug information/12983.html" rel="external">Baclofen</a>, a gamma-aminobutyric acid agonist, is widely used for treatment of spasticity. Small randomized trials in children with CP demonstrated that oral baclofen improves spasticity and range of motion and may modestly improve function [<a href="#rid29">29,43,45,46</a>]. Baclofen may be preferred over benzodiazepines due to better tolerability and lower risk of abuse. However, high-quality evidence supporting its effectiveness is lacking.</p><p></p><p class="bulletIndent1">Weight-based dosing of <a class="drug drug_pediatric" data-topicid="12983" href="/z/d/drug information/12983.html" rel="external">baclofen</a> is started at a dose of 0.5 mg/kg per day given enterally in two or three divided doses. The total daily dose can then be titrated up if necessary in weekly increments of 0.5 mg/kg per day as tolerated to a maximal dose of 2 mg/kg per day. Titration stops once an effective dose is reached; not all children require the maximal dose. The rate of titration can be slowed if side effects develop. Doses higher than 2 mg/kg per day may be necessary in some patients, depending on the response and tolerance [<a href="#rid47">47</a>].</p><p></p><p class="bulletIndent1">In older children and adolescents, initial <a class="drug drug_pediatric" data-topicid="12983" href="/z/d/drug information/12983.html" rel="external">baclofen</a> dosing starts at 5 mg two or three times per day, increased at weekly intervals to a typical maximum of 20 mg three times per day. However higher amounts, above 60 mg per day, can be administered with close monitoring.</p><p></p><p class="bulletIndent1">Common side effects include sedation, constipation, urinary retention, and nausea. Other reported side effects include confusion, hypotonia, ataxia, and paresthesias. Side effects may be minimized by slow titration but ultimately may limit treatment. Seizures and hallucination may occur if the drug is discontinued abruptly [<a href="#rid48">48</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Benzodiazepines</strong> – Benzodiazepines (eg, <a class="drug drug_pediatric" data-topicid="13223" href="/z/d/drug information/13223.html" rel="external">diazepam</a>) are widely used to treat spasticity. Small, randomized trials in children with spastic CP have demonstrated that diazepam reduces hypertonia, improves passive range of movement, and increases spontaneous movement in the short term [<a href="#rid29">29,43,49</a>].</p><p></p><p class="bulletIndent1"><a class="drug drug_pediatric" data-topicid="13223" href="/z/d/drug information/13223.html" rel="external">Diazepam</a> is given enterally at a total daily dose of 0.01 to 0.3 mg/kg divided in two to four doses (maximum 10 mg per dose). The dose is titrated gradually to effect and tolerability. Side effects include sedation, weakness, ataxia, memory disturbances, and dependence after prolonged use.</p><p></p><p class="bulletIndent1">If <a class="drug drug_pediatric" data-topicid="13223" href="/z/d/drug information/13223.html" rel="external">diazepam</a> is not effective or well tolerated, other benzodiazepines can be trialed (eg, <a class="drug drug_pediatric" data-topicid="12565" href="/z/d/drug information/12565.html" rel="external">lorazepam</a>, <a class="drug drug_pediatric" data-topicid="13170" href="/z/d/drug information/13170.html" rel="external">clonazepam</a>). Individual patients may respond better to one benzodiazepine than another. Some patients with CP may require regularly scheduled benzodiazepine for ongoing spasticity management, whereas others may use the medication only as needed (eg, for spasms or sleep disruption).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dantrolene</strong> – <a class="drug drug_pediatric" data-topicid="13203" href="/z/d/drug information/13203.html" rel="external">Dantrolene</a> is used less frequently than <a class="drug drug_pediatric" data-topicid="12983" href="/z/d/drug information/12983.html" rel="external">baclofen</a> or benzodiazepines in children with CP. Treatment with dantrolene may decrease tone, tendon reflexes, and scissoring and may improve range of motion, but there is little evidence of objective functional improvement [<a href="#rid29">29,50</a>].</p><p></p><p class="bulletIndent1">Side effects are common and include weakness, drowsiness, lethargy, paresthesias, nausea, and diarrhea [<a href="#rid43">43</a>]. The use of this drug is limited by hepatic toxicity. In a report of 1044 patients treated with <a class="drug drug_pediatric" data-topicid="13203" href="/z/d/drug information/13203.html" rel="external">dantrolene</a> for at least 60 days, hepatic toxicity occurred in 1.8 percent [<a href="#rid51">51</a>]. When additional cases reported after marketing of the drug were included in the analysis (total of 50 cases), the case-fatality rate for dantrolene-associated liver disease was 28 percent. Liver disease resolved in the remainder after discontinuation of the drug. Prior to considering starting dantrolene, potentially <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK547852%2F&amp;token=wEsKVFvqlKzpT%2BqOtddW%2Fy3%2BLj0shalBW%2BL1ZyL4try0%2B5669jWuE9Ds1a1khkWX5vkEjVCKubKK5acgUH7v%2Fw%3D%3D&amp;TOPIC_ID=118855" target="_blank">hepatotoxic medications and supplements</a> should be reviewed and weaned if possible. When dantrolene is used for treatment of spasticity in children, routine monitoring of hepatic function is necessary.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tizanidine</strong> – <a class="drug drug_pediatric" data-topicid="112669" href="/z/d/drug information/112669.html" rel="external">Tizanidine</a> is an alpha-2 adrenergic agonist agent that decreases spasticity by increasing presynaptic inhibition. There is limited experience using tizanidine in children with CP, thus it is <strong>not</strong> a first-line agent. Based on the limited available evidence, tizanidine appears to reduce spasticity compared with placebo [<a href="#rid29">29,52</a>]. When used in combination with BoNT, side effects appear to be less than the combination of BoNT plus <a class="drug drug_pediatric" data-topicid="12983" href="/z/d/drug information/12983.html" rel="external">baclofen</a> [<a href="#rid53">53</a>]. Long-term safety data are not available.</p><p></p><p class="bulletIndent1">Reported side effects include dizziness, drowsiness, gastrointestinal upset, and vomiting. Liver injury ranges from hepatitis to acute liver failure. As with <a class="drug drug_pediatric" data-topicid="13203" href="/z/d/drug information/13203.html" rel="external">dantrolene</a>, <a class="drug drug_pediatric" data-topicid="112669" href="/z/d/drug information/112669.html" rel="external">tizanidine</a> should not be combined with other hepatotoxic medications and supplements.</p><p></p><p class="headingAnchor" id="H3489645082"><span class="h3">Botulinum toxin</span><span class="headingEndMark"> — </span>Injection of BoNT into affected muscles blocks the presynaptic release of acetylcholine from motor endplates of the lower motor neuron at the myoneural junction and decreases tone by limiting muscle contraction. It is injected into several areas of the muscle. Injections must be repeated every three to eight months to maintain the effect. The potency of the different BoNT preparations (<a class="drug drug_pediatric" data-topicid="112663" href="/z/d/drug information/112663.html" rel="external">abobotulinumtoxinA</a>, <a class="drug drug_pediatric" data-topicid="129935" href="/z/d/drug information/129935.html" rel="external">incobotulinumtoxinA</a>, <a class="drug drug_pediatric" data-topicid="13089" href="/z/d/drug information/13089.html" rel="external">onabotulinumtoxinA</a>, <a class="drug drug_general" data-topicid="9155" href="/z/d/drug information/9155.html" rel="external">rimabotulinumtoxinB</a>) differs, and they should not be used interchangeably. Most reports suggest that these drugs are generally safe, but there have been case reports of life-threatening systemic toxicity. (See <a class="local">'Complications'</a> below.)</p><p class="headingAnchor" id="H710162279"><span class="h4">Patient selection</span><span class="headingEndMark"> — </span>BoNT is used in patients who have increased muscle tone that interferes with function or is likely to lead to joint contracture with growth. BoNT is used for a variety of focal indications including spastic equinus deformity (treated by injections into the gastrocnemius-soleus muscles), knee and hip flexion spasticity, and spasticity of the upper extremity [<a href="#rid43">43,54-58</a>]. The treatment can be helpful for patients with a wide range of severity (GMFCS level I to V) [<a href="#rid22">22,59</a>].</p><p>Patients &lt;4 years old and without fixed contractures are expected to have the most favorable response to BoNT treatment because the musculoskeletal and nervous systems are most pliable in growing children [<a href="#rid60">60,61</a>]. Nonetheless, BoNT also may be useful to treat focal spasticity in older children and adults.</p><p>For patients with diffuse hypertonia, BoNT can be injected into multiple muscles to treat the main foci of the generalized spasticity. Ideally, only two or three muscles will require treatment at one time. Fixed contractures are not amenable to BoNT therapy, although BoNT injections may facilitate serial casting. (See <a class="local">'Casting'</a> below.)</p><p class="headingAnchor" id="H2874402134"><span class="h4">Treatment</span><span class="headingEndMark"> — </span>Prior to treatment, a complete baseline assessment should be performed when possible by a multidisciplinary team to determine appropriateness for intervention and to establish specific treatment goals. The evaluation should include range of motion, strength, and assessment of selective motor control, muscle tone, and function.</p><p>Dosing of BoNT depends on the muscles injected, body weight, muscle bulk, the number of muscles being injected simultaneously, and the patient's response to previous therapy [<a href="#rid61">61,62</a>]. No reliable potency standard has been established for BoNT, and the biological effects may vary among preparations from different manufacturers [<a href="#rid54">54</a>]. As a result, the different BoNT preparations (<a class="drug drug_pediatric" data-topicid="112663" href="/z/d/drug information/112663.html" rel="external">abobotulinumtoxinA</a>, <a class="drug drug_pediatric" data-topicid="129935" href="/z/d/drug information/129935.html" rel="external">incobotulinumtoxinA</a>, <a class="drug drug_pediatric" data-topicid="13089" href="/z/d/drug information/13089.html" rel="external">onabotulinumtoxinA</a>, and <a class="drug drug_general" data-topicid="9155" href="/z/d/drug information/9155.html" rel="external">rimabotulinumtoxinB</a>) should not be used interchangeably, and separate dosing schemes must be established for each.</p><p>The patient should be reevaluated six to eight weeks after treatment. The effect typically lasts three to eight months, after which treatment can be repeated.</p><p class="headingAnchor" id="H3250913652"><span class="h4">Efficacy</span><span class="headingEndMark"> — </span>BoNT temporarily reduces spasticity and delays the shortening of affected muscles, as shown by case series, open label studies, and clinical trials [<a href="#rid21">21,43,59,63-69</a>]. Clinical trial evidence suggests that BoNT in combination with PT/OT modestly improves some functional outcomes, although it does not appear to improve gait [<a href="#rid21">21,29,43,68,70</a>].</p><p>A 2010 systematic review identified 10 randomized trials evaluating the efficacy and safety of BoNT as an adjunct to treatment in children with upper limb spasticity due to CP [<a href="#rid21">21</a>]. Most trials evaluated the effects of BoNT combined with PT/OT compared with PT/OT alone. BoNT improved short-term measures of spasticity and range of motion. However, in pooled analysis of three trials (109 patients), there was little improvement in self-perception or caregiver perception of performance in activities of everyday living at three months (as assessed by the Canadian Occupational Performance Measure).</p><p>In the largest pediatric trial evaluating BoNT (which was not included in the systematic review), 235 children with spastic CP and dynamic equinus foot deformity were randomized to one of two doses of BoNT or placebo. Both doses of BoNT improved muscle tone as assessed by the Modified Ashworth Scale (MAS)  (<a class="graphic graphic_table graphicRef93413" href="/z/d/graphic/93413.html" rel="external">table 1</a>) [<a href="#rid68">68</a>]. At four weeks following injection, the mean MAS score improved from 3.1 to 2.2 among patients treated with a BoNT dose of 15 units/kg/leg (mean difference -0.97; 95% CI -1.18 to -0.76), from 3.1 to 2.3 in patients treated with a dose of 10 units/kg/leg (mean difference -0.86; 95% CI -1.07 to -0.65), and from 3.2 to 2.6 in patients who received placebo (mean difference -0.48; 95% CI -0.69 to -0.27). Global clinical status, which was assessed using a 9-point scale from -4 (markedly worse) to +4 (markedly improved), was also improved (mean scores at week 4 were +1.54, +1.50, and +0.73 for the BoNT 15 units/kg/leg, BoNT 10 units/kg/leg, and placebo groups, respectively). In a secondary analysis of this trial, 77 percent of children treated with BoNT achieved their primary function goal during follow-up compared with 62 percent of those treated with placebo [<a href="#rid71">71</a>]. Goals were chosen by the parents/caregivers, with the most common goals being improved walking pattern, improved balance, and decreased frequency of falling.</p><p>Treatment benefits may be subtle and may not be obvious to the patient or caregivers. A randomized trial that included 33 children with CP and spastic diplegia showed no difference in the caregiver's satisfaction with the child's function, despite documentation of improvement in spasticity and function in the botulinum-treated group, using a variety of objective measures [<a href="#rid72">72</a>]. These observations underscore that clinicians should communicate realistic expectations prior to embarking on treatment.</p><p>The long-term effects of BoNT were evaluated in a randomized controlled trial in 64 children with spastic CP treated with BoNT or placebo for two years [<a href="#rid73">73</a>]. Changes in motor function were assessed with the Gross Motor Function Measure (GMFM) score and compared with pretreatment baseline in both groups. Changes in functional abilities were assessed using the pediatric evaluation of disability index (PEDI) score. There was a trend toward greater improvement in both GMFM and PEDI scores among placebo-treated children over the two-year study period (ie, motor function and functional ability appeared to worsen with long-term BoNT treatment); however, the findings were not statistically significant. The study was limited by its small sample size and high rates of withdrawal and loss to follow-up (30 and 9 percent of patients, respectively).</p><p>The effect of BoNT treatment on bone and soft tissue are not clear. Initial hopes that early and continued treatment with BoNT might modify the effect of spasticity on bone and soft tissue and reduce the need for later orthopedic surgery have not been born out in clinical trials. Based on the available evidence, long-term BoNT treatment does not appear to prevent contractures or reduce the need for orthopedic surgical intervention. In a randomized controlled trial in 64 children with spastic CP treated with BoNT or placebo for two years, the proportion of children who required orthopedic surgery during follow-up was similar in both groups (43 and 46 percent, respectively) [<a href="#rid73">73</a>]. Similarly, in a prospective study of long-term use of BoNT in 94 children with CP (median length of treatment 18 months), there was gradual deterioration in range of motion, despite beneficial effects on muscle tone after each injection [<a href="#rid74">74</a>]. The study did not include a control group, so it is unclear whether the range of motion deteriorated faster or slower than would have occurred without BoNT.</p><p class="headingAnchor" id="H2783050514"><span class="h4">Complications</span><span class="headingEndMark"> — </span>The majority of complications after BoNT injection are transient, mild, and self-limiting. Fever is common and may last for one to three days. Other common side effects include transient pain, local irritation, and bruising. A few patients experience temporary weakness and loss of function in the injected area, including urinary retention or constipation due to sphincter dysfunction for lower extremity injections. These symptoms usually last &lt;2 weeks and may be related to a dose that is too high or, in the case of weakness, previously unappreciated underlying muscle weakness.</p><p>Severe life-threatening systemic adverse effects, including difficulty swallowing or breathing, have been reported as rare complications [<a href="#rid75">75-77</a>]. Clinicians should be alert for the potential of systemic effects, including dysphagia, dysphonia, weakness, or dyspnea, which may occur up to several weeks after treatment. All preparations of BoNT include a boxed warning regarding potential for systemic effects. Some of these complications appear to be caused by inadvertent overdosing because potency determinations expressed in "units" varied among BoNT products. In 2008, the US Food and Drug Administration mandated changes in drug names, designed to emphasize these differences in drug potency and prevent medication errors, and updated the drug safety information for health care professionals [<a href="#rid78">78</a>].</p><p>The types and frequency of BoNT complications were illustrated in an observational study of 591 children with CP undergoing 2219 injections at a single center [<a href="#rid77">77</a>]. Adverse events attributed to systemic spread of the drug occurred in 3.6 percent of injections. Severe systemic adverse events requiring hospitalization occurred in 0.7 percent of injections and included worsening dysphagia, generalized weakness, lower respiratory tract infection, choking, and aspiration. Risk factors for experiencing an adverse event following BoNT injection in this series included severe CP (GMFCS level IV or V), known underlying dysphagia, and history of aspiration pneumonia in the past.</p><p>Most clinical trials reported similar rates of adverse events in children treated with BoNT and placebo [<a href="#rid76">76</a>]; however, the available clinical trial data are limited by small sample size and limited duration of follow-up.</p><p class="headingAnchor" id="H1950586496"><span class="h4">Secondary nonresponse</span><span class="headingEndMark"> — </span>Some patients become less responsive to BoNT over time (a phenomenon termed "secondary nonresponse") [<a href="#rid79">79-82</a>]. In some cases, this is associated with the development of neutralizing antibodies, though neutralizing antibodies do not always cause treatment nonresponse. Neutralizing antibodies to the toxin develop in 3 to 10 percent of patients after repeated injections [<a href="#rid83">83-85</a>]. The relative immunogenicity of different BoNT type A and type B preparations has not been fully established. In addition, for patients with neutralizing antibodies to one preparation (eg, a type A BoNT preparation), it is unclear whether use of another preparation (eg, a type B preparation) will be effective.</p><p class="headingAnchor" id="H2118795627"><span class="h3">Alcohol block</span><span class="headingEndMark"> — </span>Alcohol blocks with either phenol or ethanol can be used in conjunction with BoNT injections since the combination may achieve better results and the effect may last longer than either treatment alone; however, the risk of adverse effects is also increased [<a href="#rid86">86</a>]. Alcohol blocks can also be used as an alternative for patients in whom BoNT is poorly tolerated or ineffective (eg, due to development of neutralizing antibodies). Phenol and ethanol are neurolytic agents that, when given as a motor point injection, provide temporary reduction in spasticity. Clinician experience and institutional protocol typically guide selection of agent. Phenol is used most frequently.</p><p>Alcohol blocks are used specifically for nerves with only motor function (hip adductor and hamstrings most commonly, though the biceps and brachioradialis are reported) to avoid the discomfort of neurolysis near sensory nerves. Potential complications with phenol blocks include necrosis of the skin and surrounding muscle. Accidental intravascular injection can result in tinnitus and flushing. Neuritis can occur after partial destruction of a somatic nerve with subsequent regeneration; the dysesthesia or hyperesthesia that results may be worse than the original pain.</p><p>Data on the efficacy and safety of phenol blocks in children with CP are limited [<a href="#rid87">87-90</a>]. The available data suggest that, compared with BoNT, phenol blocks are associated with less improvement in spasticity and greater risk of side effects. Thus, the modest evidence regarding efficacy must be considered in the context of safety risk.</p><p class="headingAnchor" id="H3469693244"><span class="h3">Intrathecal baclofen</span><span class="headingEndMark"> — </span>For severely affected children who have significant side effects with antispasticity drugs or who have persistent and severe spasticity despite maximal doses, intrathecal <a class="drug drug_pediatric" data-topicid="12983" href="/z/d/drug information/12983.html" rel="external">baclofen</a> may be an option and is an effective intervention [<a href="#rid5">5</a>]. Intrathecal baclofen administered continuously via a pump achieves higher cerebrospinal fluid (CSF) drug levels as compared with oral administration. CSF drug levels are typically low with orally administered baclofen because of poor lipid solubility.</p><p>Intrathecal <a class="drug drug_pediatric" data-topicid="12983" href="/z/d/drug information/12983.html" rel="external">baclofen</a> reduces spasticity and clonus in severely affected patients, but it is also associated with risk for substantial complications [<a href="#rid91">91-95</a>]. Therefore, this treatment is generally restricted to patients with severe spasticity that is not responsive to other measures. Guidelines for determining patient selection and the optimal dose and placement of the catheter tip have not been established [<a href="#rid96">96</a>].</p><p>In a case series of 35 children with severe CP treated with a continuous infusion of intrathecal <a class="drug drug_pediatric" data-topicid="12983" href="/z/d/drug information/12983.html" rel="external">baclofen</a> for 18 months, patients experienced early improvement in pain and sleep and later improvement in social function and mobility [<a href="#rid97">97</a>]. However, treatment was stopped in three additional patients because of agitation or infection. Another study described the effects of intrathecal baclofen for 18 months in children with severe CP, using a group awaiting treatment as controls [<a href="#rid98">98</a>]. Children treated with intrathecal baclofen had reduced tone and spasms and improved perceived comfort and ease of nursing care. The main side effect was increased constipation.</p><p>Side effects of intrathecal <a class="drug drug_pediatric" data-topicid="12983" href="/z/d/drug information/12983.html" rel="external">baclofen</a> include lethargy, confusion, and hypotonia, which appear to be dose related and occur in up to 50 percent of patients [<a href="#rid99">99,100</a>]. Catheter-related complications include infection, seroma, and CSF leak [<a href="#rid101">101,102</a>]. Pump malfunction can also occur and must be considered promptly as serious life-threatening symptoms may arise with baclofen overdose or withdrawal.</p><p class="headingAnchor" id="H62377153"><span class="h3">Selective dorsal rhizotomy</span><span class="headingEndMark"> — </span>SDR is a surgical procedure that selectively divides parts of the dorsal lumbosacral roots of the spinal cord [<a href="#rid103">103</a>]. This interrupts the afferent limb of the reflex arc on the sensory side, thus reducing spasticity without causing paralysis. This technique may provide a small gain in function.</p><p>Which children are most likely to benefit from SDR is uncertain. The available evidence to guide treatment is limited, and practice varies considerably. There are two general categories of patients who may benefit from SDR:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Children with relatively high levels of physical function</strong> – This includes patients who are functionally limited by spasticity but with some degree of independent ambulation and with potential to make functional gains following surgery (eg, patients with spastic diplegia) [<a href="#rid104">104-107</a>]. Patient selection should be rigorous since not all patients will benefit. Historically, the optimal patients for SDR were thought to be children with spastic diplegia resulting from periventricular leukomalacia; however, over time, other etiologies have also been included (eg, hereditary spastic paraplegias). The patient's age is another important consideration. Young children (age &gt;2 years to &lt;10 years) are generally considered to be optimal candidates since they are young enough to relearn appropriate motor patterns for ambulation. Adequate cognition is necessary to allow for active engagement of the child with the intensive rehabilitation required postoperatively. Scrutiny of the degree of underlying muscle weakness is essential since long-term functional motor disability can be worsened if SDR is pursued in children with underlying muscle weakness.</p><p></p><p class="bulletIndent1">The efficacy of SDR in this setting is supported by observational data and a few small clinical trials [<a href="#rid104">104-114</a>]. In a meta-analysis of three randomized controlled trials comparing SDR plus PT with PT alone in a total of 90 children with spastic diplegia who were primarily ambulatory (most were &lt;8 years old and most had a GMFCS level of II or III), spasticity outcomes were assessed with the Ashworth scale (which ranges from 0 to 4, with higher scores reflecting more severe spasticity  (<a class="graphic graphic_table graphicRef93413" href="/z/d/graphic/93413.html" rel="external">table 1</a>)) and motor function was assessed with the GMFM-66 score (which ranges from 0 to 100, with higher scores representing greater motor function) [<a href="#rid104">104</a>]. At follow-up of 9 to 12 months, children who underwent SDR plus PT had lower Ashworth scores and slightly higher GMFM-66 scores compared with those who received PT alone (mean differences of -1.2 points for Ashworth score and 2.6 points for GMFM-66 score; 95% CIs were not reported, but both findings were statistically significant with a p value of &lt;0.01) [<a href="#rid104">104</a>]. Thus, SDR had a clinically apparent effect on spasticity but only a modest effect on motor function. The improvement in spasticity correlated with the proportion of dorsal root tissue that was transected. No serious adverse events were reported.</p><p></p><p class="bulletIndent1">In a subsequent study, 137 children (ages 3 to 9 years) with spastic diplegia and GMFCS level II to III who underwent SDR at one of five centers in England were followed prospectively for two years [<a href="#rid108">108</a>]. GMFM-66 scores improved from presurgery baseline slightly more than would be expected based on the trajectory of normative data in children with CP who did not undergo SDR (mean improvement was 3.2 per year in the study population compared with an expected rate of improvement of 1.9 per year). Greater improvements were observed in children with GMFCS level II compared with GMFCS level III. Thus, though the surgery appeared to have a measurable benefit on motor function, the effect was small. The study also found small improvements in some but not all measures of quality of life. Approximately 10 percent of children in the study experienced at least one adverse event, most commonly wound infection and persisting dysesthesias in the feet and legs. None of the adverse effects were severe.</p><p></p><p class="bulletIndent1">Long-term outcomes of SDR are described in several observational case series, which included ambulatory and nonambulatory patients (GMFCS levels I through III) [<a href="#rid109">109-115</a>]. In the largest of these series, durable improvements in lower-limb muscle tone, gross motor function, and performance of activities of daily living were found in each GMFCS group (levels I through III), although individual results varied and nearly 40 percent needed additional treatment with BoNT injection or lower extremity orthopedic surgery [<a href="#rid110">110</a>]. Patients with spastic diplegia tended to have better outcomes compared with children with quadriplegia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Severely affected nonambulatory patients</strong> – The use of SDR in the setting of severe motor impairment is emerging. Patients with severe spasticity and contractures that cause significant discomfort and/or interfere with sitting and general caretaking (eg, bathing, positioning, toileting) may have some benefit from SDR, and some centers offer surgery as an option for these patients. Patients with severe spasticity and contractures that cause significant discomfort and/or interfere with sitting and general caretaking (eg, bathing, positioning, toileting) may have some benefit from SDR, and some centers offer surgery as an option for these patients [<a href="#rid116">116-118</a>]. Many patients in this category have other comorbidities (eg, intellectual disability, seizure disorder). The goals of surgery in this setting are to improve comfort, improve sitting stability, and to ease the challenges of caretaking. SDR in severely affected patients generally requires greater extent of nerve root division, and some patients may experience troublesome weakness as a result.</p><p></p><p class="bulletIndent1">Observational studies in severely affected children (GMFCS level IV or V) suggest that SDR in combination with PT is associated with improvements in spasticity, range of motion, and urinary continence [<a href="#rid116">116-118</a>]. In a study comparing outcomes in a consecutive series of 71 children who underwent SDR with a group of 71 children (matched by age and preoperative GMFCS level) who underwent intrathecal <a class="drug drug_pediatric" data-topicid="12983" href="/z/d/drug information/12983.html" rel="external">baclofen</a> pump placement, both treatments decreased tone and improved range of motion [<a href="#rid118">118</a>]. SDR was associated with greater improvements in tone and gross motor function. Additional studies are needed to better understand the risks and benefits of SDR in this patient population.</p><p></p><p class="headingAnchor" id="H4186368471"><span class="h2">Dystonia</span></p><p class="headingAnchor" id="H1041714036"><span class="h3">Pharmacologic treatment</span><span class="headingEndMark"> — </span>Many oral agents have been used to treat dystonia, but they have not been extensively studied in rigorous controlled trials  (<a class="graphic graphic_table graphicRef75422" href="/z/d/graphic/75422.html" rel="external">table 2</a>). The therapeutic window for most of the oral agents is narrow, efficacy is often modest, and side effects frequently limit clinical benefit [<a href="#rid5">5,119,120</a>]. Parenteral agents are more difficult to administer than oral agents. </p><p>Commonly used agents include anticholinergics (eg, <a class="drug drug_pediatric" data-topicid="12863" href="/z/d/drug information/12863.html" rel="external">trihexyphenidyl</a>), benzodiazepines (eg, <a class="drug drug_pediatric" data-topicid="13170" href="/z/d/drug information/13170.html" rel="external">clonazepam</a>), oral <a class="drug drug_pediatric" data-topicid="12983" href="/z/d/drug information/12983.html" rel="external">baclofen</a>, and botulinum toxin injections. Intrathecal baclofen is typically reserved for those who are unable to tolerate or are unresponsive to oral pharmacologic agents. </p><p>The approach to treatment of dystonia is reviewed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/4887.html" rel="external">"Treatment of dystonia in children and adults"</a>.)</p><p class="headingAnchor" id="H4219371935"><span class="h3">Deep brain stimulation</span><span class="headingEndMark"> — </span>Deep brain stimulation (DBS) is generally reserved for patients with severe dystonia that has not responded to medical therapy. DBS is achieved through a microelectrode that stimulates the internal segment of the globus pallidus. It has been used for adults with severe primary dystonia (not CP) who fail treatment with pharmacologic agents and BoNT injections. Meta-analyses of DBS in patients with CP suggest that it may be effective, but further study is required to identify optimal patients for this option [<a href="#rid120">120-123</a>]. DBS for dystonia is discussed in a separate topic review. (See  <a class="medical medical_review" href="/z/d/html/4887.html" rel="external">"Treatment of dystonia in children and adults", section on 'Surgical therapy'</a>.)</p><p class="headingAnchor" id="H3686930557"><span class="h1">ORTHOPEDIC ASSESSMENT AND INTERVENTIONS</span><span class="headingEndMark"> — </span>Orthopedic interventions are directed at prevention or correction of joint deformities and maximizing function. Treatment selection is based on clinical evaluation, severity of symptoms, the efficacy of the intervention, and patient and caregiver goals. The goals of orthopedic intervention are to improve positioning and gait and to prevent pain.</p><p class="headingAnchor" id="H3568592794"><span class="h2">Gait analysis</span><span class="headingEndMark"> — </span>Gait analysis, using physical examination, videotaping, force plates, electromyography, and computerized analysis of limb motion, can be used as an assessment tool to identify abnormalities in muscle function and limb alignment and to evaluate both the indications for and the effects of surgery [<a href="#rid124">124-126</a>].</p><p class="headingAnchor" id="H3592106880"><span class="h2">Casting</span><span class="headingEndMark"> — </span>Serial casting in the upper and lower extremities is used to stretch the shortened muscles, correct joint deformities, and improve range of motion. Systematic reviews of observational studies and a few small randomized trials reveal that ankle casting results in small improvements in range of motion and short-term improvements in contractures, but it is unclear if these effects are clinically meaningful over the long term [<a href="#rid5">5,29,127-129</a>]. A small clinical trial showed that the addition of wrist casting to botulinum neurotoxin (BoNT) injections and occupational therapy (OT) resulted in greater improvement of muscle tone, spasticity, and passive range of motion at the 12-week follow-up [<a href="#rid130">130</a>]. Longer-term benefits are uncertain.</p><p>Active goal-directed and strength training following casting are used to help sustain improvements in function [<a href="#rid20">20,129</a>].</p><p class="headingAnchor" id="H1646014068"><span class="h2">Surgery for contractures and bony deformities</span><span class="headingEndMark"> — </span>Children with CP can develop fixed joint deformities and contractures that lead to alterations in the normal growth and development of the skeletal system. Surgical procedures for children with CP can be broadly divided into soft tissue procedures on tendons and muscles and bone procedures.</p><p class="headingAnchor" id="H1137531102"><span class="h3">Soft tissue surgery</span><span class="headingEndMark"> — </span>Lengthening, release, or transfer of muscle tendon units can improve function and delay or prevent deformities. These procedures are typically considered when abnormal muscle action or contractures interfere with function or care. They are often performed as part of a single-event multilevel surgery (SEMLS). (See <a class="local">'Multilevel surgery'</a> below.)</p><p>Muscle-tendon surgeries result in small improvements in gait function. As an example, one study prospectively evaluated the effect of muscle-tendon surgery in 30 patients with spastic diplegia [<a href="#rid131">131</a>]. Operations were performed at a mean age of 8.7 years. Gait velocity and stride length increased by 25 and 18 percent over preoperative values, respectively, nine months after surgery and were maintained for two years. However, the Gross Motor Function Measure (GMFM) score changed little after surgery.</p><p>In a nonrandomized prospective study comparing upper extremity tendon transfer surgery (n = 16) with BoNT injections (n = 13) or regular physical therapy (n = 10) in 39 children (ages 4 to 16 years), upper extremity tendon transfer surgery resulted in a greater degree of functional mobility and improved movement-related quality of life scores compared with nonsurgical management [<a href="#rid132">132</a>].</p><p class="headingAnchor" id="H2698108945"><span class="h3">Bone surgery</span><span class="headingEndMark"> — </span>Normal growth and development of the skeletal system depends on the bones being exposed to normal forces. When these forces are altered by abnormal muscle tone and abnormal weight-bearing patterns, secondary skeletal deformities can develop. Muscle-tendon surgery alone may not be sufficient to correct or prevent these deformities. Bone procedures may be used to permanently eliminate joint motion and correct deformity by slowing changes to the growth plate (eg, hemiepiphysiodesis) or by changing alignment and/or fusing the joint (eg, osteotomy).</p><p class="headingAnchor" id="H4151298972"><span class="h3">Multilevel surgery</span><span class="headingEndMark"> — </span>SEMLS is widely used in the management of children with CP. It involves multiple corrections of soft tissue and/or bony abnormalities at different anatomic levels performed in one surgery under one anesthesia [<a href="#rid133">133-136</a>]. Historically, serial surgeries were performed over a number of years. The advantage of SEMLS is that the child requires fewer surgeries and a shorter recovery period.</p><p class="headingAnchor" id="H566070487"><span class="h2">Hip disorders</span><span class="headingEndMark"> — </span>Disorders of the hip are common complications of CP. These include progressive hip dysplasia, subluxation, and dislocation with degeneration and pain [<a href="#rid137">137</a>]. Although the hip is usually normal at birth, progressive dysplasia results from abnormal growth of the proximal femur and acetabulum. Nonambulatory children with quadriplegia are at the highest risk of hip disorders. Nearly half of nonambulatory children with spastic quadriplegia develop hip subluxation by five years of age as compared with 21 percent of those with diplegia [<a href="#rid138">138</a>].</p><p>Screening and management of hip disorders in children with CP is outlined in a Care Pathway of the Academy of Cerebral Palsy and Developmental Medicine [<a href="#rid139">139</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevention</strong> – The most effective preventive strategy is early detection and appropriate management. Small observational studies have found decreased rates of early hip subluxation in children who start an abducted standing program before the age of 12 months [<a href="#rid140">140,141</a>].</p><p></p><p class="bulletIndent1">Interventions to control spasticity do not appear to have an effect on hip subluxation [<a href="#rid142">142</a>]. A 2017 systematic review of available trials and observational studies identified no intervention with a substantial treatment effect at prevention hip subluxation [<a href="#rid143">143</a>]. In one clinical trial included in the systematic review, 90 children at risk for hip dysplasia were assigned to combination treatment with BoNT and hip bracing or to no treatment [<a href="#rid144">144</a>]. Similar rates of progressive hip displacement were seen in the treatment group as compared with controls. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Screening</strong> – Because earlier surgical intervention is associated with better outcomes, we suggest that all children with CP undergo routine surveillance for hip dysplasia, consisting of physical examination and radiologic screening [<a href="#rid29">29,138,145-147</a>]. Screening programs appear to reduce the rate of hip dislocation when paired with appropriate and timely interventions [<a href="#rid148">148</a>]. Radiologic screening is performed with a supine anteroposterior radiograph of the pelvis with a bolster placed under the knees. Physical examination can occasionally detect clinical signs of subluxation in radiographically mild subluxation. The affected leg may be shortened and internally rotated, and there may be a palpable fullness in the gluteal region. The interval of screening varies depending on the child's motor function and other risk factors [<a href="#rid149">149</a>]. In nonambulatory patients, radiographs are generally obtained every 6 to 12 months.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Index of suspicion</strong> – In addition to routine surveillance, the clinician should maintain a high index of suspicion for hip dislocation/subluxation in children and adults with CP who present with acute or chronic pain of uncertain etiology. Radiologic evaluation of the entire leg should be performed if hip pain can be elicited on physical examination, if passive range of motion is reduced compared with previous examinations, or for significant caregiver concern.</p><p></p><p class="bulletIndent1">Leg pain in a child or adult with a dislocated or severely subluxated hip may also be due to a fracture [<a href="#rid150">150</a>]. (See  <a class="medical medical_review" href="/z/d/html/6176.html" rel="external">"Cerebral palsy: Overview of management and prognosis", section on 'Bone health'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong> – Treatment options for hip subluxation and dislocation include noninvasive abduction bracing, soft-tissue releases, reconstructive femoral and/or pelvic osteotomies, and salvage procedures such as valgus osteotomy of the proximal femur or proximal femoral resection. Bracing may help improve quality of life and delay need for surgery for some children [<a href="#rid151">151</a>]. In most children with hip subluxation, femoral and possibly pelvic osteotomies are indicated [<a href="#rid152">152,153</a>]. However, the surgical management required to prevent recurrent subluxation depends on the preoperative severity of the hip subluxation and acetabular dysplasia [<a href="#rid154">154</a>]. Routine hip surveillance and timely intervention are key to avoiding the need for salvage surgery [<a href="#rid155">155</a>].</p><p></p><p class="bulletIndent1">Children who undergo soft tissue procedures alone are likely to need subsequent surgery, particularly if they have either severe spasticity (ie, Gross Motor Function Classification System [GMFCS] level IV or V) or radiologic evidence of hip dysplasia prior to intervention [<a href="#rid156">156</a>].</p><p></p><p class="headingAnchor" id="H3736343367"><span class="h2">Neuromuscular scoliosis</span><span class="headingEndMark"> — </span>Scoliosis is common in patients with CP, affecting approximately one-quarter to one-half of patients [<a href="#rid157">157,158</a>]. The incidence varies depending on the severity of motor impairment. Most children with severe motor impairment (GMFCS level IV or V) develop some degree of scoliosis by adolescence; in some patients, the onset may be as early as age 5 or 6 years [<a href="#rid159">159</a>]. In a study of 666 children with CP, the rate of moderate to severe scoliosis correlated directly with GMFCS level: 2 percent for GMFCS level I, 7 percent for GMFCS level II/III, and 30 percent for GMFCS level IV/V [<a href="#rid157">157</a>].</p><p>Neuromuscular scoliosis in patients with CP is generally progressive. It can result in pelvic obliquity and seating difficulties. Caregiving can become more challenging, and pain can be a complicating factor. In addition, scoliosis can have adverse long-term effects on cardiopulmonary and gastrointestinal function [<a href="#rid160">160</a>]. (See  <a class="medical medical_review" href="/z/d/html/4320.html" rel="external">"Chest wall diseases and restrictive physiology", section on 'Kyphosis and scoliosis'</a>.)</p><p>Unlike idiopathic scoliosis, the classic curve pattern in CP is a long C-shaped kyphoscoliotic curve  (<a class="graphic graphic_diagnosticimage graphicRef119626" href="/z/d/graphic/119626.html" rel="external">image 1</a>). However, a wide range of spinal deformities can be seen.</p><p>Management of neuromuscular scoliosis is complex and best accomplished with a multidisciplinary team approach. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nonsurgical management</strong> – Nonsurgical management includes spinal bracing and use of molded wheelchair inserts to improve sitting balance and optimize comfort and positioning. Spinal bracing may improve sitting function [<a href="#rid161">161,162</a>]. However, progression is likely, particularly in patients with early onset (before age 10 years) and/or &gt;40 degree curvature [<a href="#rid158">158,159</a>]. Antispasticity medications do not play a role in limiting progression of the curve but may help with overall comfort if muscle spasm is contributing to pain. Many children with significant neuromuscular scoliosis from CP are already taking medication for tone management. (See <a class="local">'Spasticity'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Surgical management</strong> – Surgery for children with CP and scoliosis varies by age. Children who have a considerable amount of growth remaining may undergo growth-friendly spinal instrumentation (eg, growing rods) to prevent progression of severe curves [<a href="#rid163">163-165</a>]. For children closer to skeletal maturity, spinal fusion surgery is an option. Criteria for patient selection are not standardized. Reasonable candidates may include those who meet the following criteria [<a href="#rid158">158</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>&gt;40 to 50 degree curvature that is progressive and interferes with sitting</p><p class="bulletIndent2"><span class="glyph">•</span>Age &gt;10 years (though surgery can be considered at a younger age if the curvature is severe)</p><p class="bulletIndent2"><span class="glyph">•</span>Adequate hip range of motion to allow proper seating postoperatively</p><p class="bulletIndent2"><span class="glyph">•</span>Stable nutritional and medical status (though there may be considerable medical complexity)</p><p></p><p class="bulletIndent1">The decision to pursue spinal fusion is multifaceted and should be grounded in the patient and caregiver goals and realistic expectations, as well as an understanding of the risks and benefits [<a href="#rid166">166</a>]. Because of the increased risks of spinal surgery in this population (as discussed below), surgery should be considered only when the expected benefits outweigh both the risks associated with surgery and the risks of not intervening (ie, the negative consequences of the natural history of progressive scoliosis). Preoperative evaluation should include a comprehensive medical evaluation, including assessment of cardiopulmonary function, nutritional status, and neurologic status. A multidisciplinary approach to surgery to anticipate potential risks and complications is desirable. This includes input from orthopedic surgery, general medicine, anesthesia, and other specialties as indicated [<a href="#rid167">167</a>].</p><p></p><p class="bulletIndent1">Spinal fusion surgery for patients with CP generally involves multilevel internal fixation. The goal of surgery is to achieve solid bony fusion of the spine that corrects the curvature and results in a well-balanced spine with a level pelvis  (<a class="graphic graphic_diagnosticimage graphicRef119626" href="/z/d/graphic/119626.html" rel="external">image 1</a>) [<a href="#rid158">158</a>]. It may involve posterior fusion only or anterior release with posterior fusion; surgery may be performed as a staged or same-day procedure [<a href="#rid168">168</a>]. Different surgical techniques have been described, and the technical details are beyond the scope of this topic review. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy of scoliosis surgery</strong> – Data evaluating the efficacy of scoliosis surgery in patients with CP are limited to small retrospective cohort studies and case series [<a href="#rid169">169-171</a>]. In a systematic review of 51 observational reports, most studies reported good achievement of correction of the scoliosis deformity (typically measured by improvement in the Cobb angle  (<a class="graphic graphic_diagnosticimage graphicRef62495" href="/z/d/graphic/62495.html" rel="external">image 2</a>)) [<a href="#rid169">169</a>]. There was a trend toward improvement in measures of caregiver satisfaction and quality of life; however, there was minimal to no improvement in gross motor or overall function. In a representative multicenter study that reported outcomes in 69 consecutive children and adolescents (mean age 13.5 years) with severe CP (GMFCS level IV or V) who underwent scoliosis surgery and were followed for five years, the Cobb angle improved from a mean of 82 degrees preoperatively to 28 degrees at one year postoperatively and then increased slightly to 32 degrees by five years [<a href="#rid171">171</a>]. Pelvic obliquity improved from a mean of 27 degrees preoperatively to 8 degrees at five years. There were modest improvements in some measures of caregiver-reported disease-specific quality of life, most notably in domains of personal care (mean improvement 7 points on a 100-point scale), positioning (mean improvement 9 points on a 100-point scale), and comfort (mean improvement 9 points on a 100-point scale) [<a href="#rid172">172,173</a>]. Data on long-term health outcomes, such as respiratory function, are limited. However, scoliosis surgery may reduce mortality rate, likely driven by reduction in subsequent respiratory complications. In a population-based registry of children with CP and scoliosis, mortality rates were higher in children treated nonsurgically than in those treated surgically (8.7 versus 5.3 per 1000 follow-up years) [<a href="#rid174">174</a>]. Respiratory cause of death during follow-up was more common in those treated nonsurgically (76 versus 38 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Complications</strong> – Reported complication rates of scoliosis surgery in patients with CP range from 25 to 50 percent [<a href="#rid169">169,171,175</a>]. These rates are considerably higher than in adolescents with idiopathic scoliosis; children with CP also tend to require longer duration of hospitalization postoperatively. </p><p></p><p class="bulletIndent1">The most common complications include [<a href="#rid169">169,175</a>]: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Surgical site infection</p><p class="bulletIndent2"><span class="glyph">•</span>Postoperative pneumonia</p><p class="bulletIndent2"><span class="glyph">•</span>Major blood loss</p><p class="bulletIndent2"><span class="glyph">•</span>Pseudoarthrosis (failure of fusion)</p><p class="bulletIndent2"><span class="glyph">•</span>Other hardware complications (eg, malposition, prominence, loosening of instrumentation)</p><p></p><p class="bulletIndent1">Other reported complications include [<a href="#rid169">169,171,175</a>]: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Neurologic injury</p><p class="bulletIndent2"><span class="glyph">•</span>Prolonged mechanical ventilation </p><p class="bulletIndent2"><span class="glyph">•</span>Pleural effusion</p><p class="bulletIndent2"><span class="glyph">•</span>Pneumothorax</p><p class="bulletIndent2"><span class="glyph">•</span>Pancreatitis</p><p class="bulletIndent2"><span class="glyph">•</span>Prolonged ileus</p><p class="bulletIndent2"><span class="glyph">•</span>Decubitus ulcer</p><p></p><p class="bulletIndent1">Perioperative mortality is uncommon for children with CP undergoing scoliosis surgery, with reported rates ranging from 0 to 10 percent [<a href="#rid169">169</a>]. In a multicenter study of 808 patients undergoing spinal surgery for neuromuscular scoliosis, the mortality rate was 0.01 percent at 120 days and 1.1 percent by two years [<a href="#rid176">176</a>]. </p><p></p><p class="bulletIndent1">Risk factors for experiencing a major perioperative complication include [<a href="#rid175">175,177</a>]: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Nonambulatory status</p><p class="bulletIndent2"><span class="glyph">•</span>Preexisting pulmonary compromise</p><p class="bulletIndent2"><span class="glyph">•</span>High degree of medical complexity</p><p class="bulletIndent2"><span class="glyph">•</span>Large intraoperative blood loss </p><p></p><p class="headingAnchor" id="H3332395022"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/140087.html" rel="external">"Society guideline links: Cerebral palsy"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/119468.html" rel="external">"Society guideline links: Dystonia in children and adults"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/121704.html" rel="external">"Society guideline links: Developmental screening"</a>.)</p><p class="headingAnchor" id="H3802320907"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or email these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient education" and the keyword[s] of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/82901.html" rel="external">"Patient education: Cerebral palsy (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H2662644971"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial evaluation and approach to treatment</strong> – All children with cerebral palsy (CP) have altered motor function, affecting posture, coordination, and balance. Treatment interventions should begin at the time of suspected diagnosis and focus on maximizing the child's independence in daily functional activities and reducing the extent of disability. Assessment of the child's functional status guides treatment selection and allows for monitoring of change over time. (See  <a class="medical medical_review" href="/z/d/html/6176.html" rel="external">"Cerebral palsy: Overview of management and prognosis", section on 'Functional evaluation'</a> and  <a class="medical medical_review" href="/z/d/html/6167.html" rel="external">"Cerebral palsy: Classification and clinical features", section on 'Functional classification systems'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Physical and occupational therapy</strong> – Physical and occupational therapy (PT/OT) are established and vital parts of treatment programs for CP. PT and OT are typically incorporated into care of all patients at a young age. (See <a class="local">'Physical and occupational therapy'</a> above.)</p><p></p><p class="bulletIndent1">In addition, some patients with CP require devices to help promote function, mobility, and participation. These include braces, orthotics, standers, seating systems, and mobility devices. (See <a class="local">'Orthotics and other devices'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Spasticity treatment options</strong> – Treatment options for spasticity may vary according to several factors, including the child's age, goals for treatment, comorbid conditions, risk of adverse effects from treatment, regional distribution of spasticity, and the response to any prior treatments. Our approach to managing spasticity in children with CP is as follows:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Oral antispasticity medications</strong> – For children with generalized spasticity, we suggest oral antispasticity medications with <a class="drug drug_pediatric" data-topicid="12983" href="/z/d/drug information/12983.html" rel="external">baclofen</a> or benzodiazepines as first-line therapy (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). <a class="drug drug_pediatric" data-topicid="13203" href="/z/d/drug information/13203.html" rel="external">Dantrolene</a> and <a class="drug drug_pediatric" data-topicid="112669" href="/z/d/drug information/112669.html" rel="external">tizanidine</a> are alternative options. (See <a class="local">'Oral antispasticity drugs'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Botulinum toxin</strong> – For treatment of localized or segmental spasticity, we suggest botulinum neurotoxin (BoNT) injections (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). Dosing varies by the specific BoNT preparation used (<a class="drug drug_pediatric" data-topicid="112663" href="/z/d/drug information/112663.html" rel="external">abobotulinumtoxinA</a>, <a class="drug drug_pediatric" data-topicid="129935" href="/z/d/drug information/129935.html" rel="external">incobotulinumtoxinA</a>, <a class="drug drug_pediatric" data-topicid="13089" href="/z/d/drug information/13089.html" rel="external">onabotulinumtoxinA</a>, and <a class="drug drug_general" data-topicid="9155" href="/z/d/drug information/9155.html" rel="external">rimabotulinumtoxinB</a>); they should <strong>not</strong> be used interchangeably. (See <a class="local">'Botulinum toxin'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Alcohol blocks</strong> – Alcohol blocks can be used in conjunction with BoNT injections or as an alternative for patients who do not tolerate or respond to BoNT. (See <a class="local">'Alcohol block'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Other options</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Selective dorsal rhizotomy</strong> – For patients with spastic diplegia who have mild to moderate motor impairment, no significant weakness, and are cognitively able to participate in post-surgery rehabilitation, selective dorsal rhizotomy (SDR) may be an option as an alternative or adjunct intervention to improve function. SDR may also be used for selected patients with severe motor impairment. (See <a class="local">'Selective dorsal rhizotomy'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Intrathecal </strong><a class="drug drug_pediatric" data-topicid="12983" href="/z/d/drug information/12983.html" rel="external">baclofen</a> – For severely affected children who have significant side effects with oral antispasticity drugs or who do not achieve adequate response despite maximal dose, an intrathecal baclofen pump may provide better control of spasticity as well as improved comfort and positioning. (See <a class="local">'Intrathecal baclofen'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dystonia treatment options</strong> – Many oral agents have been used to treat dystonia, but they have not been extensively studied in rigorous controlled trials  (<a class="graphic graphic_table graphicRef75422" href="/z/d/graphic/75422.html" rel="external">table 2</a>). The approach to treating dystonia is reviewed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/4887.html" rel="external">"Treatment of dystonia in children and adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Orthopedic interventions </strong>– Orthopedic interventions are directed at prevention or correction of deformities and maximizing function. Options include bracing, casting, and soft-tissue or bone surgeries. (See <a class="local">'Orthopedic assessment and interventions'</a> above.)</p><p></p><p class="headingAnchor" id="H3786673751"><span class="h1">ACKNOWLEDGMENTS</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Geoffrey Miller, MD and Laurie Glader, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Rosenbaum P, Paneth N, Leviton A, et al. A report: the definition and classification of cerebral palsy April 2006. Dev Med Child Neurol Suppl 2007; 109:8.</a></li><li><a class="nounderline abstract_t">Morgan C, Fetters L, Adde L, et al. Early Intervention for Children Aged 0 to 2 Years With or at High Risk of Cerebral Palsy: International Clinical Practice Guideline Based on Systematic Reviews. JAMA Pediatr 2021; 175:846.</a></li><li><a class="nounderline abstract_t">Russman BS, Tilton A, Gormley ME Jr. Cerebral palsy: a rational approach to a treatment protocol, and the role of botulinum toxin in treatment. Muscle Nerve Suppl 1997; 6:S181.</a></li><li><a class="nounderline abstract_t">Morgan C, Darrah J, Gordon AM, et al. Effectiveness of motor interventions in infants with cerebral palsy: a systematic review. Dev Med Child Neurol 2016; 58:900.</a></li><li><a class="nounderline abstract_t">Novak I, Morgan C, Fahey M, et al. State of the Evidence Traffic Lights 2019: Systematic Review of Interventions for Preventing and Treating Children with Cerebral Palsy. Curr Neurol Neurosci Rep 2020; 20:3.</a></li><li><a class="nounderline abstract_t">Sakzewski L, Ziviani J, Abbott DF, et al. Randomized trial of constraint-induced movement therapy and bimanual training on activity outcomes for children with congenital hemiplegia. Dev Med Child Neurol 2011; 53:313.</a></li><li><a class="nounderline abstract_t">Sakzewski L, Ziviani J, Boyd RN. Efficacy of upper limb therapies for unilateral cerebral palsy: a meta-analysis. Pediatrics 2014; 133:e175.</a></li><li><a class="nounderline abstract_t">Jackman M, Sakzewski L, Morgan C, et al. Interventions to improve physical function for children and young people with cerebral palsy: international clinical practice guideline. Dev Med Child Neurol 2022; 64:536.</a></li><li><a class="nounderline abstract_t">Jobst C, D'Souza SJ, Causton N, et al. Somatosensory Plasticity in Hemiplegic Cerebral Palsy Following Constraint Induced Movement Therapy. Pediatr Neurol 2022; 126:80.</a></li><li><a class="nounderline abstract_t">Ramey SL, DeLuca SC, Stevenson RD, et al. Constraint-Induced Movement Therapy for Cerebral Palsy: A Randomized Trial. Pediatrics 2021; 148.</a></li><li><a class="nounderline abstract_t">Huang HH, Fetters L, Hale J, McBride A. Bound for success: a systematic review of constraint-induced movement therapy in children with cerebral palsy supports improved arm and hand use. Phys Ther 2009; 89:1126.</a></li><li><a class="nounderline abstract_t">Charles JR, Wolf SL, Schneider JA, Gordon AM. Efficacy of a child-friendly form of constraint-induced movement therapy in hemiplegic cerebral palsy: a randomized control trial. Dev Med Child Neurol 2006; 48:635.</a></li><li><a class="nounderline abstract_t">Deluca SC, Echols K, Law CR, Ramey SL. Intensive pediatric constraint-induced therapy for children with cerebral palsy: randomized, controlled, crossover trial. J Child Neurol 2006; 21:931.</a></li><li><a class="nounderline abstract_t">Hoare BJ, Wasiak J, Imms C, Carey L. Constraint-induced movement therapy in the treatment of the upper limb in children with hemiplegic cerebral palsy. Cochrane Database Syst Rev 2007; :CD004149.</a></li><li><a class="nounderline abstract_t">Tinderholt Myrhaug H, Østensjø S, Larun L, et al. Intensive training of motor function and functional skills among young children with cerebral palsy: a systematic review and meta-analysis. BMC Pediatr 2014; 14:292.</a></li><li><a class="nounderline abstract_t">Law MC, Darrah J, Pollock N, et al. Focus on function: a cluster, randomized controlled trial comparing child- versus context-focused intervention for young children with cerebral palsy. Dev Med Child Neurol 2011; 53:621.</a></li><li><a class="nounderline abstract_t">Novak I, Cusick A, Lannin N. Occupational therapy home programs for cerebral palsy: double-blind, randomized, controlled trial. Pediatrics 2009; 124:e606.</a></li><li><a class="nounderline abstract_t">Ketelaar M, Vermeer A, Hart H, et al. Effects of a functional therapy program on motor abilities of children with cerebral palsy. Phys Ther 2001; 81:1534.</a></li><li><a class="nounderline abstract_t">Booth ATC, Buizer AI, Meyns P, et al. The efficacy of functional gait training in children and young adults with cerebral palsy: a systematic review and meta-analysis. Dev Med Child Neurol 2018; 60:866.</a></li><li><a class="nounderline abstract_t">Toovey R, Bernie C, Harvey AR, et al. Task-specific gross motor skills training for ambulant school-aged children with cerebral palsy: a systematic review. BMJ Paediatr Open 2017; 1:e000078.</a></li><li><a class="nounderline abstract_t">Hoare BJ, Wallen MA, Imms C, et al. Botulinum toxin A as an adjunct to treatment in the management of the upper limb in children with spastic cerebral palsy (UPDATE). Cochrane Database Syst Rev 2010; :CD003469.</a></li><li><a class="nounderline abstract_t">Boyd RN, Hays RM. Current evidence for the use of botulinum toxin type A in the management of children with cerebral palsy: a systematic review. Eur J Neurol 2001; 8 Suppl 5:1.</a></li><li><a class="nounderline abstract_t">Lannin N, Scheinberg A, Clark K. AACPDM systematic review of the effectiveness of therapy for children with cerebral palsy after botulinum toxin A injections. Dev Med Child Neurol 2006; 48:533.</a></li><li><a class="nounderline abstract_t">Fehlings D, Novak I, Berweck S, et al. Botulinum toxin assessment, intervention and follow-up for paediatric upper limb hypertonicity: international consensus statement. Eur J Neurol 2010; 17 Suppl 2:38.</a></li><li><a class="nounderline abstract_t">Butler JM, Scianni A, Ada L. Effect of cardiorespiratory training on aerobic fitness and carryover to activity in children with cerebral palsy: a systematic review. Int J Rehabil Res 2010; 33:97.</a></li><li><a class="nounderline abstract_t">Rogers A, Furler BL, Brinks S, Darrah J. A systematic review of the effectiveness of aerobic exercise interventions for children with cerebral palsy: an AACPDM evidence report. Dev Med Child Neurol 2008; 50:808.</a></li><li><a class="nounderline abstract_t">Soares EG, Gusmão CHV, Souto DO. Efficacy of aerobic exercise on the functioning and quality of life of children and adolescents with cerebral palsy: A systematic review and meta-analysis. Dev Med Child Neurol 2023; 65:1292.</a></li><li><a class="nounderline abstract_t">Heussen N, Häusler M. Equine-Assisted Therapies for Children With Cerebral Palsy: A Meta-analysis. Pediatrics 2022; 150.</a></li><li><a class="nounderline abstract_t">Novak I, McIntyre S, Morgan C, et al. A systematic review of interventions for children with cerebral palsy: state of the evidence. Dev Med Child Neurol 2013; 55:885.</a></li><li><a class="nounderline abstract_t">Te Velde A, Morgan C, Finch-Edmondson M, et al. Neurodevelopmental Therapy for Cerebral Palsy: A Meta-analysis. Pediatrics 2022; 149.</a></li><li><a class="nounderline abstract_t">Butler C, Darrah J. Effects of neurodevelopmental treatment (NDT) for cerebral palsy: an AACPDM evidence report. Dev Med Child Neurol 2001; 43:778.</a></li><li><a class="nounderline abstract_t">Martin L, Baker R, Harvey A. A systematic review of common physiotherapy interventions in school-aged children with cerebral palsy. Phys Occup Ther Pediatr 2010; 30:294.</a></li><li><a class="nounderline abstract_t">Bar-Haim S, Harries N, Nammourah I, et al. Effectiveness of motor learning coaching in children with cerebral palsy: a randomized controlled trial. Clin Rehabil 2010; 24:1009.</a></li><li><a class="nounderline abstract_t">Vargas S, Camilli G. A meta-analysis of research on sensory integration treatment. Am J Occup Ther 1999; 53:189.</a></li><li><a class="nounderline abstract_t">Winkle M, Crowe TK, Hendrix I. Service dogs and people with physical disabilities partnerships: a systematic review. Occup Ther Int 2012; 19:54.</a></li><li><a class="nounderline abstract_t">Darrah J, Watkins B, Chen L, et al. Conductive education intervention for children with cerebral palsy: an AACPDM evidence report. Dev Med Child Neurol 2004; 46:187.</a></li><li><a class="nounderline abstract_t">Güçhan Z, Mutlu A. The effectiveness of taping on children with cerebral palsy: a systematic review. Dev Med Child Neurol 2017; 59:26.</a></li><li><a class="nounderline abstract_t">Liptak GS. Complementary and alternative therapies for cerebral palsy. Ment Retard Dev Disabil Res Rev 2005; 11:156.</a></li><li><a class="nounderline abstract_t">Lintanf M, Bourseul JS, Houx L, et al. Effect of ankle-foot orthoses on gait, balance and gross motor function in children with cerebral palsy: a systematic review and meta-analysis. Clin Rehabil 2018; 32:1175.</a></li><li><a class="nounderline abstract_t">Garbellini S, Robert Y, Randall M, et al. Rationale for prescription, and effectiveness of, upper limb orthotic intervention for children with cerebral palsy: a systematic review. Disabil Rehabil 2018; 40:1361.</a></li><li><a class="nounderline abstract_t">Dunning K, O'Dell MW, Kluding P, McBride K. Peroneal Stimulation for Foot Drop After Stroke: A Systematic Review. Am J Phys Med Rehabil 2015; 94:649.</a></li><li><a class="nounderline abstract_t">Davidson B, Schoen N, Sedighim S, et al. Intrathecal baclofen versus selective dorsal rhizotomy for children with cerebral palsy who are nonambulant: a systematic review. J Neurosurg Pediatr 2019; :1.</a></li><li><a class="nounderline abstract_t">Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society, Delgado MR, Hirtz D, et al. Practice parameter: pharmacologic treatment of spasticity in children and adolescents with cerebral palsy (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology 2010; 74:336.</a></li><li><a class="nounderline abstract_t">Lumsden DE, Crowe B, Basu A, et al. Pharmacological management of abnormal tone and movement in cerebral palsy. Arch Dis Child 2019; 104:775.</a></li><li><a class="nounderline abstract_t">Milla PJ, Jackson AD. A controlled trial of baclofen in children with cerebral palsy. J Int Med Res 1977; 5:398.</a></li><li><a class="nounderline abstract_t">Scheinberg A, Hall K, Lam LT, O'Flaherty S. Oral baclofen in children with cerebral palsy: a double-blind cross-over pilot study. J Paediatr Child Health 2006; 42:715.</a></li><li><a class="nounderline abstract_t">Lubsch L, Habersang R, Haase M, Luedtke S. Oral baclofen and clonidine for treatment of spasticity in children. J Child Neurol 2006; 21:1090.</a></li><li><a class="nounderline abstract_t">Terrence CF, Fromm GH. Complications of baclofen withdrawal. Arch Neurol 1981; 38:588.</a></li><li><a class="nounderline abstract_t">Mathew A, Mathew MC, Thomas M, Antonisamy B. The efficacy of diazepam in enhancing motor function in children with spastic cerebral palsy. J Trop Pediatr 2005; 51:109.</a></li><li><a class="nounderline abstract_t">Joynt RL, Leonard JA Jr. Dantrolene sodium suspension in treatment of spastic cerebral palsy. Dev Med Child Neurol 1980; 22:755.</a></li><li><a class="nounderline abstract_t">Utili R, Boitnott JK, Zimmerman HJ. Dantrolene-associated hepatic injury. Incidence and character. Gastroenterology 1977; 72:610.</a></li><li><a class="nounderline abstract_t">Vásquez-Briceño A, Arellano-Saldaña ME, León-Hernández SR, Morales-Osorio MG. [The usefulness of tizanidine. A one-year follow-up of the treatment of spasticity in infantile cerebral palsy]. Rev Neurol 2006; 43:132.</a></li><li><a class="nounderline abstract_t">Dai AI, Aksoy SN, Demiryürek AT. Comparison of Efficacy and Side Effects of Oral Baclofen Versus Tizanidine Therapy with Adjuvant Botulinum Toxin Type A in Children With Cerebral Palsy and Spastic Equinus Foot Deformity. J Child Neurol 2016; 31:184.</a></li><li><a class="nounderline abstract_t">Simpson DM, Gracies JM, Graham HK, et al. Assessment: Botulinum neurotoxin for the treatment of spasticity (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008; 70:1691.</a></li><li><a class="nounderline abstract_t">Koman LA, Mooney JF 3rd, Smith BP, et al. Botulinum toxin type A neuromuscular blockade in the treatment of lower extremity spasticity in cerebral palsy: a randomized, double-blind, placebo-controlled trial. BOTOX Study Group. J Pediatr Orthop 2000; 20:108.</a></li><li><a class="nounderline abstract_t">Koman LA, Brashear A, Rosenfeld S, et al. Botulinum toxin type a neuromuscular blockade in the treatment of equinus foot deformity in cerebral palsy: a multicenter, open-label clinical trial. Pediatrics 2001; 108:1062.</a></li><li><a class="nounderline abstract_t">Love SC, Novak I, Kentish M, et al. Botulinum toxin assessment, intervention and after-care for lower limb spasticity in children with cerebral palsy: international consensus statement. Eur J Neurol 2010; 17 Suppl 2:9.</a></li><li><a class="nounderline abstract_t">Van Campenhout A, Bar-On L, Desloovere K, et al. Motor endplate-targeted botulinum toxin injections of the gracilis muscle in children with cerebral palsy. Dev Med Child Neurol 2015; 57:476.</a></li><li><a class="nounderline abstract_t">Copeland L, Edwards P, Thorley M, et al. Botulinum toxin A for nonambulatory children with cerebral palsy: a double blind randomized controlled trial. J Pediatr 2014; 165:140.</a></li><li><a class="nounderline abstract_t">Pascual-Pascual SI, Pascual-Castroviejo I. Safety of botulinum toxin type A in children younger than 2 years. Eur J Paediatr Neurol 2009; 13:511.</a></li><li><a class="nounderline abstract_t">Molenaers G, Van Campenhout A, Fagard K, et al. The use of botulinum toxin A in children with cerebral palsy, with a focus on the lower limb. J Child Orthop 2010; 4:183.</a></li><li><a class="nounderline abstract_t">Heinen F, Desloovere K, Schroeder AS, et al. The updated European Consensus 2009 on the use of Botulinum toxin for children with cerebral palsy. Eur J Paediatr Neurol 2010; 14:45.</a></li><li><a class="nounderline abstract_t">Petersen MC, Palmer FB. Advances in prevention and treatment of cerebral palsy. Ment Retard Dev Disabil Res Rev 2001; 7:30.</a></li><li><a class="nounderline abstract_t">Dursun N, Dursun E, Alican D. The role of botulinum toxin a in the management of lower limb spasticity in patients with cerebral palsy. Int J Clin Pract 2002; 56:564.</a></li><li><a class="nounderline abstract_t">Baker R, Jasinski M, Maciag-Tymecka I, et al. Botulinum toxin treatment of spasticity in diplegic cerebral palsy: a randomized, double-blind, placebo-controlled, dose-ranging study. Dev Med Child Neurol 2002; 44:666.</a></li><li><a class="nounderline abstract_t">Polak F, Morton R, Ward C, et al. Double-blind comparison study of two doses of botulinum toxin A injected into calf muscles in children with hemiplegic cerebral palsy. Dev Med Child Neurol 2002; 44:551.</a></li><li><a class="nounderline abstract_t">Cardoso ES, Rodrigues BM, Barroso M, et al. Botulinum toxin type A for the treatment of the spastic equinus foot in cerebral palsy. Pediatr Neurol 2006; 34:106.</a></li><li><a class="nounderline abstract_t">Delgado MR, Tilton A, Russman B, et al. AbobotulinumtoxinA for Equinus Foot Deformity in Cerebral Palsy: A Randomized Controlled Trial. Pediatrics 2016; 137:e20152830.</a></li><li><a class="nounderline abstract_t">Dabrowski E, Chambers HG, Gaebler-Spira D, et al. IncobotulinumtoxinA Efficacy/Safety in Upper-Limb Spasticity in Pediatric Cerebral Palsy: Randomized Controlled Trial. Pediatr Neurol 2021; 123:10.</a></li><li><a class="nounderline abstract_t">Tedroff K, Löwing K, Haglund-Akerlind Y, et al. Botulinum toxin A treatment in toddlers with cerebral palsy. Acta Paediatr 2010; 99:1156.</a></li><li><a class="nounderline abstract_t">Tilton A, Russman B, Aydin R, et al. AbobotulinumtoxinA (Dysport®) Improves Function According to Goal Attainment in Children With Dynamic Equinus Due to Cerebral Palsy. J Child Neurol 2017; 32:482.</a></li><li><a class="nounderline abstract_t">Bjornson K, Hays R, Graubert C, et al. Botulinum toxin for spasticity in children with cerebral palsy: a comprehensive evaluation. Pediatrics 2007; 120:49.</a></li><li><a class="nounderline abstract_t">Moore AP, Ade-Hall RA, Smith CT, et al. Two-year placebo-controlled trial of botulinum toxin A for leg spasticity in cerebral palsy. Neurology 2008; 71:122.</a></li><li><a class="nounderline abstract_t">Tedroff K, Granath F, Forssberg H, Haglund-Akerlind Y. Long-term effects of botulinum toxin A in children with cerebral palsy. Dev Med Child Neurol 2009; 51:120.</a></li><li><a class="nounderline abstract_t">O'Flaherty SJ, Janakan V, Morrow AM, et al. Adverse events and health status following botulinum toxin type A injections in children with cerebral palsy. Dev Med Child Neurol 2011; 53:125.</a></li><li><a class="nounderline abstract_t">Edwards P, Sakzewski L, Copeland L, et al. Safety of Botulinum Toxin Type A for Children With Nonambulatory Cerebral Palsy. Pediatrics 2015; 136:895.</a></li><li><a class="nounderline abstract_t">Paget SP, Swinney CM, Burton KLO, et al. Systemic adverse events after botulinum neurotoxin A injections in children with cerebral palsy. Dev Med Child Neurol 2018; 60:1172.</a></li><li class="breakAll">US Food and Drug Administration. Information for healthcare professionals: OnabotulinumtoxinA (marketed as Botox/Botox Cosmetic), AbobotulinumtoxinA (marketed as Dysport) and RimabotulinumtoxinB (marketed as Myobloc). www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm174949.htm (Accessed on August 05, 2009).</li><li><a class="nounderline abstract_t">Müller K, Mix E, Adib Saberi F, et al. Prevalence of neutralising antibodies in patients treated with botulinum toxin type A for spasticity. J Neural Transm (Vienna) 2009; 116:579.</a></li><li><a class="nounderline abstract_t">Dressler D. Clinical features of antibody-induced complete secondary failure of botulinum toxin therapy. Eur Neurol 2002; 48:26.</a></li><li><a class="nounderline abstract_t">Benecke R. Clinical relevance of botulinum toxin immunogenicity. BioDrugs 2012; 26:e1.</a></li><li><a class="nounderline abstract_t">Herrmann J, Geth K, Mall V, et al. Clinical impact of antibody formation to botulinum toxin A in children. Ann Neurol 2004; 55:732.</a></li><li><a class="nounderline abstract_t">Greene P, Fahn S, Diamond B. Development of resistance to botulinum toxin type A in patients with torticollis. Mov Disord 1994; 9:213.</a></li><li><a class="nounderline abstract_t">Brin MF. Botulinum toxin: chemistry, pharmacology, toxicity, and immunology. Muscle Nerve Suppl 1997; 6:S146.</a></li><li><a class="nounderline abstract_t">Oshima M, Deitiker P, Hastings-Ison T, et al. Antibody responses to botulinum neurotoxin type A of toxin-treated spastic equinus children with cerebral palsy: A randomized clinical trial comparing two injection schedules. J Neuroimmunol 2017; 306:31.</a></li><li><a class="nounderline abstract_t">Gracies JM, Elovic E, McGuire J, Simpson DM. Traditional pharmacological treatments for spasticity. Part I: Local treatments. Muscle Nerve Suppl 1997; 6:S61.</a></li><li><a class="nounderline abstract_t">Wong AM, Chen CL, Chen CP, et al. Clinical effects of botulinum toxin A and phenol block on gait in children with cerebral palsy. Am J Phys Med Rehabil 2004; 83:284.</a></li><li><a class="nounderline abstract_t">Gonnade N, Lokhande V, Ajij M, et al. Phenol Versus Botulinum Toxin A Injection in Ambulatory Cerebral Palsy Spastic Diplegia: A Comparative Study. J Pediatr Neurosci 2017; 12:338.</a></li><li><a class="nounderline abstract_t">Kolaski K, Ajizian SJ, Passmore L, et al. Safety profile of multilevel chemical denervation procedures using phenol or botulinum toxin or both in a pediatric population. Am J Phys Med Rehabil 2008; 87:556.</a></li><li><a class="nounderline abstract_t">Gooch JL, Patton CP. Combining botulinum toxin and phenol to manage spasticity in children. Arch Phys Med Rehabil 2004; 85:1121.</a></li><li><a class="nounderline abstract_t">Motta F, Buonaguro V, Stignani C. The use of intrathecal baclofen pump implants in children and adolescents: safety and complications in 200 consecutive cases. J Neurosurg 2007; 107:32.</a></li><li><a class="nounderline abstract_t">Pin TW, McCartney L, Lewis J, Waugh MC. Use of intrathecal baclofen therapy in ambulant children and adolescents with spasticity and dystonia of cerebral origin: a systematic review. Dev Med Child Neurol 2011; 53:885.</a></li><li><a class="nounderline abstract_t">Butler C, Campbell S. Evidence of the effects of intrathecal baclofen for spastic and dystonic cerebral palsy. AACPDM Treatment Outcomes Committee Review Panel. Dev Med Child Neurol 2000; 42:634.</a></li><li><a class="nounderline abstract_t">Lam SK, Mayer RR, Vedantam A, et al. Readmission and complications within 30 days after intrathecal baclofen pump placement. Dev Med Child Neurol 2018; 60:1038.</a></li><li><a class="nounderline abstract_t">Buizer AI, Martens BHM, Grandbois van Ravenhorst C, et al. Effect of continuous intrathecal baclofen therapy in children: a systematic review. Dev Med Child Neurol 2019; 61:128.</a></li><li><a class="nounderline abstract_t">Brennan PM, Whittle IR. Intrathecal baclofen therapy for neurological disorders: a sound knowledge base but many challenges remain. Br J Neurosurg 2008; 22:508.</a></li><li><a class="nounderline abstract_t">Ramstad K, Jahnsen R, Lofterod B, Skjeldal OH. Continuous intrathecal baclofen therapy in children with cerebral palsy - when does improvement emerge? Acta Paediatr 2010; 99:1661.</a></li><li><a class="nounderline abstract_t">Morton RE, Gray N, Vloeberghs M. Controlled study of the effects of continuous intrathecal baclofen infusion in non-ambulant children with cerebral palsy. Dev Med Child Neurol 2011; 53:736.</a></li><li><a class="nounderline abstract_t">Albright AL. Baclofen in the treatment of cerebral palsy. J Child Neurol 1996; 11:77.</a></li><li><a class="nounderline abstract_t">Albright AL, Gilmartin R, Swift D, et al. Long-term intrathecal baclofen therapy for severe spasticity of cerebral origin. J Neurosurg 2003; 98:291.</a></li><li><a class="nounderline abstract_t">Ghosh D, Mainali G, Khera J, Luciano M. Complications of intrathecal baclofen pumps in children: experience from a tertiary care center. Pediatr Neurosurg 2013; 49:138.</a></li><li class="breakAll">www.accessdata.fda.gov/drugsatfda_docs/label/2015/022462s008lbl.pdf (Accessed on February 23, 2015).</li><li><a class="nounderline abstract_t">Aquilina K, Graham D, Wimalasundera N. Selective dorsal rhizotomy: an old treatment re-emerging. Arch Dis Child 2015; 100:798.</a></li><li><a class="nounderline abstract_t">McLaughlin J, Bjornson K, Temkin N, et al. Selective dorsal rhizotomy: meta-analysis of three randomized controlled trials. Dev Med Child Neurol 2002; 44:17.</a></li><li><a class="nounderline abstract_t">Steinbok P, Reiner AM, Beauchamp R, et al. A randomized clinical trial to compare selective posterior rhizotomy plus physiotherapy with physiotherapy alone in children with spastic diplegic cerebral palsy. Dev Med Child Neurol 1997; 39:178.</a></li><li><a class="nounderline abstract_t">Wright FV, Sheil EM, Drake JM, et al. Evaluation of selective dorsal rhizotomy for the reduction of spasticity in cerebral palsy: a randomized controlled tria. Dev Med Child Neurol 1998; 40:239.</a></li><li><a class="nounderline abstract_t">McLaughlin JF, Bjornson KF, Astley SJ, et al. Selective dorsal rhizotomy: efficacy and safety in an investigator-masked randomized clinical trial. Dev Med Child Neurol 1998; 40:220.</a></li><li><a class="nounderline abstract_t">Summers J, Coker B, Eddy S, et al. Selective dorsal rhizotomy in ambulant children with cerebral palsy: an observational cohort study. Lancet Child Adolesc Health 2019; 3:455.</a></li><li><a class="nounderline abstract_t">Mittal S, Farmer JP, Al-Atassi B, et al. Long-term functional outcome after selective posterior rhizotomy. J Neurosurg 2002; 97:315.</a></li><li><a class="nounderline abstract_t">Dudley RW, Parolin M, Gagnon B, et al. Long-term functional benefits of selective dorsal rhizotomy for spastic cerebral palsy. J Neurosurg Pediatr 2013; 12:142.</a></li><li><a class="nounderline abstract_t">Bolster EA, van Schie PE, Becher JG, et al. Long-term effect of selective dorsal rhizotomy on gross motor function in ambulant children with spastic bilateral cerebral palsy, compared with reference centiles. Dev Med Child Neurol 2013; 55:610.</a></li><li><a class="nounderline abstract_t">Josenby AL, Wagner P, Jarnlo GB, et al. Motor function after selective dorsal rhizotomy: a 10-year practice-based follow-up study. Dev Med Child Neurol 2012; 54:429.</a></li><li><a class="nounderline abstract_t">Tedroff K, Löwing K, Åström E. A prospective cohort study investigating gross motor function, pain, and health-related quality of life 17 years after selective dorsal rhizotomy in cerebral palsy. Dev Med Child Neurol 2015; 57:484.</a></li><li><a class="nounderline abstract_t">Cole GF, Farmer SE, Roberts A, et al. Selective dorsal rhizotomy for children with cerebral palsy: the Oswestry experience. Arch Dis Child 2007; 92:781.</a></li><li><a class="nounderline abstract_t">Veerbeek BE, Lamberts RP, Kosel E, et al. More than 25 years after selective dorsal rhizotomy: physical status, quality of life, and levels of anxiety and depression in adults with cerebral palsy. J Neurosurg 2022; 136:689.</a></li><li><a class="nounderline abstract_t">D'Aquino D, Moussa AA, Ammar A, et al. Selective dorsal rhizotomy for the treatment of severe spastic cerebral palsy: efficacy and therapeutic durability in GMFCS grade IV and V children. Acta Neurochir (Wien) 2018; 160:811.</a></li><li><a class="nounderline abstract_t">Ingale H, Ughratdar I, Muquit S, et al. Selective dorsal rhizotomy as an alternative to intrathecal baclofen pump replacement in GMFCS grades 4 and 5 children. Childs Nerv Syst 2016; 32:321.</a></li><li><a class="nounderline abstract_t">Kan P, Gooch J, Amini A, et al. Surgical treatment of spasticity in children: comparison of selective dorsal rhizotomy and intrathecal baclofen pump implantation. Childs Nerv Syst 2008; 24:239.</a></li><li><a class="nounderline abstract_t">Fehlings D, Brown L, Harvey A, et al. Pharmacological and neurosurgical interventions for managing dystonia in cerebral palsy: a systematic review. Dev Med Child Neurol 2018; 60:356.</a></li><li><a class="nounderline abstract_t">Bohn E, Goren K, Switzer L, et al. Pharmacological and neurosurgical interventions for individuals with cerebral palsy and dystonia: a systematic review update and meta-analysis. Dev Med Child Neurol 2021; 63:1038.</a></li><li><a class="nounderline abstract_t">Koy A, Hellmich M, Pauls KA, et al. Effects of deep brain stimulation in dyskinetic cerebral palsy: A meta-analysis. Mov Disord 2013; 28:647.</a></li><li><a class="nounderline abstract_t">Vidailhet M, Yelnik J, Lagrange C, et al. Bilateral pallidal deep brain stimulation for the treatment of patients with dystonia-choreoathetosis cerebral palsy: a prospective pilot study. Lancet Neurol 2009; 8:709.</a></li><li><a class="nounderline abstract_t">Marks WA, Honeycutt J, Acosta F Jr, et al. Dystonia due to cerebral palsy responds to deep brain stimulation of the globus pallidus internus. Mov Disord 2011; 26:1748.</a></li><li><a class="nounderline abstract_t">Bleck EE. Management of the lower extremities in children who have cerebral palsy. J Bone Joint Surg Am 1990; 72:140.</a></li><li><a class="nounderline abstract_t">Sutherland DH, Davids JR. Common gait abnormalities of the knee in cerebral palsy. Clin Orthop Relat Res 1993; :139.</a></li><li><a class="nounderline abstract_t">Baddar A, Granata K, Damiano DL, et al. Ankle and knee coupling in patients with spastic diplegia: effects of gastrocnemius-soleus lengthening. J Bone Joint Surg Am 2002; 84-A:736.</a></li><li><a class="nounderline abstract_t">Autti-Rämö I, Suoranta J, Anttila H, et al. Effectiveness of upper and lower limb casting and orthoses in children with cerebral palsy: an overview of review articles. Am J Phys Med Rehabil 2006; 85:89.</a></li><li><a class="nounderline abstract_t">Blackmore AM, Boettcher-Hunt E, Jordan M, Chan MD. A systematic review of the effects of casting on equinus in children with cerebral palsy: an evidence report of the AACPDM. Dev Med Child Neurol 2007; 49:781.</a></li><li><a class="nounderline abstract_t">Tustin K, Patel A. A Critical Evaluation of the Updated Evidence for Casting for Equinus Deformity in Children with Cerebral Palsy. Physiother Res Int 2017; 22.</a></li><li><a class="nounderline abstract_t">Dursun N, Gokbel T, Akarsu M, et al. Intermittent serial casting for wrist flexion deformity in children with spastic cerebral palsy: a randomized controlled trial. Dev Med Child Neurol 2021; 63:743.</a></li><li><a class="nounderline abstract_t">Abel MF, Damiano DL, Pannunzio M, Bush J. Muscle-tendon surgery in diplegic cerebral palsy: functional and mechanical changes. J Pediatr Orthop 1999; 19:366.</a></li><li><a class="nounderline abstract_t">Van Heest AE, Bagley A, Molitor F, James MA. Tendon transfer surgery in upper-extremity cerebral palsy is more effective than botulinum toxin injections or regular, ongoing therapy. J Bone Joint Surg Am 2015; 97:529.</a></li><li><a class="nounderline abstract_t">McGinley JL, Dobson F, Ganeshalingam R, et al. Single-event multilevel surgery for children with cerebral palsy: a systematic review. Dev Med Child Neurol 2012; 54:117.</a></li><li><a class="nounderline abstract_t">Lamberts RP, Burger M, du Toit J, Langerak NG. A Systematic Review of the Effects of Single-Event Multilevel Surgery on Gait Parameters in Children with Spastic Cerebral Palsy. PLoS One 2016; 11:e0164686.</a></li><li><a class="nounderline abstract_t">Edwards TA, Theologis T, Wright J. Predictors affecting outcome after single-event multilevel surgery in children with cerebral palsy: a systematic review. Dev Med Child Neurol 2018; 60:1201.</a></li><li><a class="nounderline abstract_t">Jones MD, Gardner R, Pyman J, et al. Long-term Outcomes Following Multilevel Surgery in Cerebral Palsy. J Pediatr Orthop 2020; 40:351.</a></li><li><a class="nounderline abstract_t">Flynn JM, Miller F. Management of hip disorders in patients with cerebral palsy. J Am Acad Orthop Surg 2002; 10:198.</a></li><li><a class="nounderline abstract_t">Gordon GS, Simkiss DE. A systematic review of the evidence for hip surveillance in children with cerebral palsy. J Bone Joint Surg Br 2006; 88:1492.</a></li><li class="breakAll">Hip Surveillance in Cerebral Palsy. AACPDM Hip Surveillance Care Pathway Team: M O’Donnell (team lead), T Mayson (project manager and clinical examination sub-group leader), S Miller (radiology sub-group leader), R Cairns, K Graham, S Love, F Miller, K Mulpuri, U Narayanan, H Read, B Shore, K Stannage, P Thomason, J Vargus-Adams, L Wiggins, K Willoughby, M Wynter. Available at: https://www.aacpdm.org/publications/care-pathways/hip-surveillance (Accessed on November 13, 2018).</li><li><a class="nounderline abstract_t">Macias-Merlo L, Bagur-Calafat C, Girabent-Farrés M, A Stuberg W. Effects of the standing program with hip abduction on hip acetabular development in children with spastic diplegia cerebral palsy. Disabil Rehabil 2016; 38:1075.</a></li><li><a class="nounderline abstract_t">Martinsson C, Himmelmann K. Abducted Standing in Children With Cerebral Palsy: Effects on Hip Development After 7 Years. Pediatr Phys Ther 2021; 33:101.</a></li><li><a class="nounderline abstract_t">Silva S, Nowicki P, Caird MS, et al. A comparison of hip dislocation rates and hip containment procedures after selective dorsal rhizotomy versus intrathecal baclofen pump insertion in nonambulatory cerebral palsy patients. J Pediatr Orthop 2012; 32:853.</a></li><li><a class="nounderline abstract_t">Miller SD, Juricic M, Hesketh K, et al. Prevention of hip displacement in children with cerebral palsy: a systematic review. Dev Med Child Neurol 2017; 59:1130.</a></li><li><a class="nounderline abstract_t">Graham HK, Boyd R, Carlin JB, et al. Does botulinum toxin a combined with bracing prevent hip displacement in children with cerebral palsy and "hips at risk"? A randomized, controlled trial. J Bone Joint Surg Am 2008; 90:23.</a></li><li><a class="nounderline abstract_t">Dobson F, Boyd RN, Parrott J, et al. Hip surveillance in children with cerebral palsy. Impact on the surgical management of spastic hip disease. J Bone Joint Surg Br 2002; 84:720.</a></li><li><a class="nounderline abstract_t">Wynter M, Gibson N, Willoughby KL, et al. Australian hip surveillance guidelines for children with cerebral palsy: 5-year review. Dev Med Child Neurol 2015; 57:808.</a></li><li><a class="nounderline abstract_t">Hägglund G, Andersson S, Düppe H, et al. Prevention of dislocation of the hip in children with cerebral palsy. The first ten years of a population-based prevention programme. J Bone Joint Surg Br 2005; 87:95.</a></li><li><a class="nounderline abstract_t">Hägglund G, Alriksson-Schmidt A, Lauge-Pedersen H, et al. Prevention of dislocation of the hip in children with cerebral palsy: 20-year results of a population-based prevention programme. Bone Joint J 2014; 96-B:1546.</a></li><li><a class="nounderline abstract_t">Abousamra O, Er MS, Rogers KJ, et al. Hip Reconstruction in Children With Unilateral Cerebral Palsy and Hip Dysplasia. J Pediatr Orthop 2016; 36:834.</a></li><li><a class="nounderline abstract_t">Pritchett JW. The untreated unstable hip in severe cerebral palsy. Clin Orthop Relat Res 1983; :169.</a></li><li><a class="nounderline abstract_t">Kim BR, Yoon JA, Han HJ, et al. Efficacy of a Hip Brace for Hip Displacement in Children With Cerebral Palsy: A Randomized Clinical Trial. JAMA Netw Open 2022; 5:e2240383.</a></li><li><a class="nounderline abstract_t">Rutz E, Vavken P, Camathias C, et al. Long-term results and outcome predictors in one-stage hip reconstruction in children with cerebral palsy. J Bone Joint Surg Am 2015; 97:500.</a></li><li><a class="nounderline abstract_t">El-Sobky TA, Fayyad TA, Kotb AM, Kaldas B. Bony reconstruction of hip in cerebral palsy children Gross Motor Function Classification System levels III to V: a systematic review. J Pediatr Orthop B 2018; 27:221.</a></li><li><a class="nounderline abstract_t">Zakrzewski AM, Bryant AJ, McCarthy JJ. Can Over-containment Prevent Recurrence in Children With Cerebral Palsy and Hip Dysplasia Undergoing Hip Reconstruction? J Pediatr Orthop 2022; 42:300.</a></li><li><a class="nounderline abstract_t">Marcström A, Hägglund G, Alriksson-Schmidt AI. Hip pain in children with cerebral palsy: a population-based registry study of risk factors. BMC Musculoskelet Disord 2019; 20:62.</a></li><li><a class="nounderline abstract_t">Shore BJ, Yu X, Desai S, et al. Adductor surgery to prevent hip displacement in children with cerebral palsy: the predictive role of the Gross Motor Function Classification System. J Bone Joint Surg Am 2012; 94:326.</a></li><li><a class="nounderline abstract_t">Persson-Bunke M, Hägglund G, Lauge-Pedersen H, et al. Scoliosis in a total population of children with cerebral palsy. Spine (Phila Pa 1976) 2012; 37:E708.</a></li><li><a class="nounderline abstract_t">McCarthy JJ, D'Andrea LP, Betz RR, Clements DH. Scoliosis in the child with cerebral palsy. J Am Acad Orthop Surg 2006; 14:367.</a></li><li><a class="nounderline abstract_t">Yoshida K, Kajiura I, Suzuki T, Kawabata H. Natural history of scoliosis in cerebral palsy and risk factors for progression of scoliosis. J Orthop Sci 2018; 23:649.</a></li><li><a class="nounderline abstract_t">Baldwin KD, Cahill PJ, Sponseller PD, et al. BMI change following spinal fusion for neuromuscular scoliosis surgery. Spine Deform 2020; 8:1081.</a></li><li><a class="nounderline abstract_t">Kotwicki T, Jozwiak M. Conservative management of neuromuscular scoliosis: personal experience and review of literature. Disabil Rehabil 2008; 30:792.</a></li><li><a class="nounderline abstract_t">Blomkvist A, Olsson K, Eek MN. The effect of spinal bracing on sitting function in children with neuromuscular scoliosis. Prosthet Orthot Int 2018; 42:592.</a></li><li><a class="nounderline abstract_t">Thompson W, Thakar C, Rolton DJ, et al. The use of magnetically-controlled growing rods to treat children with early-onset scoliosis: early radiological results in 19 children. Bone Joint J 2016; 98-B:1240.</a></li><li><a class="nounderline abstract_t">Subramanian T, Ahmad A, Mardare DM, et al. A six-year observational study of 31 children with early-onset scoliosis treated using magnetically controlled growing rods with a minimum follow-up of two years. Bone Joint J 2018; 100-B:1187.</a></li><li><a class="nounderline abstract_t">Thakar C, Kieser DC, Mardare M, et al. Systematic review of the complications associated with magnetically controlled growing rods for the treatment of early onset scoliosis. Eur Spine J 2018; 27:2062.</a></li><li><a class="nounderline abstract_t">Garrity B, Berry J, Crofton C, et al. Parent-to-Parent Advice on Considering Spinal Fusion in Children with Neuromuscular Scoliosis. J Pediatr 2019; 213:149.</a></li><li><a class="nounderline abstract_t">Berry JG, Glaspy T, Eagan B, et al. Pediatric complex care and surgery comanagement: Preparation for spinal fusion. J Child Health Care 2020; 24:402.</a></li><li><a class="nounderline abstract_t">Jackson T, Yaszay B, Sponseller PD, et al. Factors associated with surgical approach and outcomes in cerebral palsy scoliosis. Eur Spine J 2019; 28:567.</a></li><li><a class="nounderline abstract_t">Toovey R, Harvey A, Johnson M, et al. Outcomes after scoliosis surgery for children with cerebral palsy: a systematic review. Dev Med Child Neurol 2017; 59:690.</a></li><li><a class="nounderline abstract_t">Sewell MD, Wallace C, Malagelada F, et al. Does Spinal Fusion and Scoliosis Correction Improve Activity and Participation for Children With GMFCS level 4 and 5 Cerebral Palsy? Medicine (Baltimore) 2015; 94:e1907.</a></li><li><a class="nounderline abstract_t">Miyanji F, Nasto LA, Sponseller PD, et al. Assessing the Risk-Benefit Ratio of Scoliosis Surgery in Cerebral Palsy: Surgery Is Worth It. J Bone Joint Surg Am 2018; 100:556.</a></li><li><a class="nounderline abstract_t">DiFazio RL, Vessey JA, Miller PE, et al. Health-related quality of life and caregiver burden after hip reconstruction and spinal fusion in children with spastic cerebral palsy. Dev Med Child Neurol 2022; 64:80.</a></li><li><a class="nounderline abstract_t">Bottos M, Feliciangeli A, Sciuto L, et al. Functional status of adults with cerebral palsy and implications for treatment of children. Dev Med Child Neurol 2001; 43:516.</a></li><li><a class="nounderline abstract_t">Ahonen M, Helenius I, Gissler M, Jeglinsky-Kankainen I. Mortality and Causes of Death in Children With Cerebral Palsy With Scoliosis Treated With and Without Surgery. Neurology 2023; 101:e1787.</a></li><li><a class="nounderline abstract_t">Toll BJ, Samdani AF, Janjua MB, et al. Perioperative complications and risk factors in neuromuscular scoliosis surgery. J Neurosurg Pediatr 2018; 22:207.</a></li><li><a class="nounderline abstract_t">Matsumoto H, Fano AN, Herman ET, et al. Mortality in Neuromuscular Early Onset Scoliosis Following Spinal Deformity Surgery. J Pediatr Orthop 2022; 42:e234.</a></li><li><a class="nounderline abstract_t">Jain A, Sponseller PD, Shah SA, et al. Subclassification of GMFCS Level-5 Cerebral Palsy as a Predictor of Complications and Health-Related Quality of Life After Spinal Arthrodesis. J Bone Joint Surg Am 2016; 98:1821.</a></li></ol></div><div id="topicVersionRevision">Topic 118855 Version 32.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17370477" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : A report: the definition and classification of cerebral palsy April 2006.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33999106" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Early Intervention for Children Aged 0 to 2 Years With or at High Risk of Cerebral Palsy: International Clinical Practice Guideline Based on Systematic Reviews.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9826990" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Cerebral palsy: a rational approach to a treatment protocol, and the role of botulinum toxin in treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27027732" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Effectiveness of motor interventions in infants with cerebral palsy: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32086598" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : State of the Evidence Traffic Lights 2019: Systematic Review of Interventions for Preventing and Treating Children with Cerebral Palsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21401585" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Randomized trial of constraint-induced movement therapy and bimanual training on activity outcomes for children with congenital hemiplegia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24366991" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Efficacy of upper limb therapies for unilateral cerebral palsy: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34549424" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Interventions to improve physical function for children and young people with cerebral palsy: international clinical practice guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34742103" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Somatosensory Plasticity in Hemiplegic Cerebral Palsy Following Constraint Induced Movement Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34649982" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Constraint-Induced Movement Therapy for Cerebral Palsy: A Randomized Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19729391" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Bound for success: a systematic review of constraint-induced movement therapy in children with cerebral palsy supports improved arm and hand use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16836774" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Efficacy of a child-friendly form of constraint-induced movement therapy in hemiplegic cerebral palsy: a randomized control trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17092457" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Intensive pediatric constraint-induced therapy for children with cerebral palsy: randomized, controlled, crossover trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17443542" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Constraint-induced movement therapy in the treatment of the upper limb in children with hemiplegic cerebral palsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25475608" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Intensive training of motor function and functional skills among young children with cerebral palsy: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21569012" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Focus on function: a cluster, randomized controlled trial comparing child- versus context-focused intervention for young children with cerebral palsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19770175" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Occupational therapy home programs for cerebral palsy: double-blind, randomized, controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11688590" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Effects of a functional therapy program on motor abilities of children with cerebral palsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29512110" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : The efficacy of functional gait training in children and young adults with cerebral palsy: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29637118" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Task-specific gross motor skills training for ambulant school-aged children with cerebral palsy: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20091546" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Botulinum toxin A as an adjunct to treatment in the management of the upper limb in children with spastic cerebral palsy (UPDATE).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11851730" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Current evidence for the use of botulinum toxin type A in the management of children with cerebral palsy: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16700950" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : AACPDM systematic review of the effectiveness of therapy for children with cerebral palsy after botulinum toxin A injections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20633178" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Botulinum toxin assessment, intervention and follow-up for paediatric upper limb hypertonicity: international consensus statement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19770667" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Effect of cardiorespiratory training on aerobic fitness and carryover to activity in children with cerebral palsy: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18811714" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : A systematic review of the effectiveness of aerobic exercise interventions for children with cerebral palsy: an AACPDM evidence report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36895173" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Efficacy of aerobic exercise on the functioning and quality of life of children and adolescents with cerebral palsy: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35656779" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Equine-Assisted Therapies for Children With Cerebral Palsy: A Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23962350" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : A systematic review of interventions for children with cerebral palsy: state of the evidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35607928" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Neurodevelopmental Therapy for Cerebral Palsy: A Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11730153" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Effects of neurodevelopmental treatment (NDT) for cerebral palsy: an AACPDM evidence report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20735200" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : A systematic review of common physiotherapy interventions in school-aged children with cerebral palsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20576667" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Effectiveness of motor learning coaching in children with cerebral palsy: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10200842" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : A meta-analysis of research on sensory integration treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21858889" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Service dogs and people with physical disabilities partnerships: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14995089" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Conductive education intervention for children with cerebral palsy: an AACPDM evidence report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27476831" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : The effectiveness of taping on children with cerebral palsy: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15977320" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Complementary and alternative therapies for cerebral palsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29714066" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Effect of ankle-foot orthoses on gait, balance and gross motor function in children with cerebral palsy: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28286982" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Rationale for prescription, and effectiveness of, upper limb orthotic intervention for children with cerebral palsy: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26035725" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Peroneal Stimulation for Foot Drop After Stroke: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31628286" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Intrathecal baclofen versus selective dorsal rhizotomy for children with cerebral palsy who are nonambulant: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20101040" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Practice parameter: pharmacologic treatment of spasticity in children and adolescents with cerebral palsy (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30948360" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Pharmacological management of abnormal tone and movement in cerebral palsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/338390" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : A controlled trial of baclofen in children with cerebral palsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17044900" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Oral baclofen in children with cerebral palsy: a double-blind cross-over pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17156708" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Oral baclofen and clonidine for treatment of spasticity in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6791618" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Complications of baclofen withdrawal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15840761" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : The efficacy of diazepam in enhancing motor function in children with spastic cerebral palsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7004956" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Dantrolene sodium suspension in treatment of spastic cerebral palsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/838213" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Dantrolene-associated hepatic injury. Incidence and character.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16871477" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : [The usefulness of tizanidine. A one-year follow-up of the treatment of spasticity in infantile cerebral palsy].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25999301" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Comparison of Efficacy and Side Effects of Oral Baclofen Versus Tizanidine Therapy with Adjuvant Botulinum Toxin Type A in Children With Cerebral Palsy and Spastic Equinus Foot Deformity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18458229" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Assessment: Botulinum neurotoxin for the treatment of spasticity (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10641699" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Botulinum toxin type A neuromuscular blockade in the treatment of lower extremity spasticity in cerebral palsy: a randomized, double-blind, placebo-controlled trial. BOTOX Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11694682" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Botulinum toxin type a neuromuscular blockade in the treatment of equinus foot deformity in cerebral palsy: a multicenter, open-label clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20633177" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Botulinum toxin assessment, intervention and after-care for lower limb spasticity in children with cerebral palsy: international consensus statement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25557985" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Motor endplate-targeted botulinum toxin injections of the gracilis muscle in children with cerebral palsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24630348" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Botulinum toxin A for nonambulatory children with cerebral palsy: a double blind randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19036619" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Safety of botulinum toxin type A in children younger than 2 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21629371" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : The use of botulinum toxin A in children with cerebral palsy, with a focus on the lower limb.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19914110" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : The updated European Consensus 2009 on the use of Botulinum toxin for children with cerebral palsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11241880" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Advances in prevention and treatment of cerebral palsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12425363" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : The role of botulinum toxin a in the management of lower limb spasticity in patients with cerebral palsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12418791" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Botulinum toxin treatment of spasticity in diplegic cerebral palsy: a randomized, double-blind, placebo-controlled, dose-ranging study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12206622" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Double-blind comparison study of two doses of botulinum toxin A injected into calf muscles in children with hemiplegic cerebral palsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16458821" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Botulinum toxin type A for the treatment of the spastic equinus foot in cerebral palsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26812925" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : AbobotulinumtoxinA for Equinus Foot Deformity in Cerebral Palsy: A Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34339951" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : IncobotulinumtoxinA Efficacy/Safety in Upper-Limb Spasticity in Pediatric Cerebral Palsy: Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20222884" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Botulinum toxin A treatment in toddlers with cerebral palsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28068857" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : AbobotulinumtoxinA (Dysport®) Improves Function According to Goal Attainment in Children With Dynamic Equinus Due to Cerebral Palsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17606561" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Botulinum toxin for spasticity in children with cerebral palsy: a comprehensive evaluation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18606966" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Two-year placebo-controlled trial of botulinum toxin A for leg spasticity in cerebral palsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19191845" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Long-term effects of botulinum toxin A in children with cerebral palsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21244412" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Adverse events and health status following botulinum toxin type A injections in children with cerebral palsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26482662" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Safety of Botulinum Toxin Type A for Children With Nonambulatory Cerebral Palsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30146721" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Systemic adverse events after botulinum neurotoxin A injections in children with cerebral palsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30146721" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Systemic adverse events after botulinum neurotoxin A injections in children with cerebral palsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19352590" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Prevalence of neutralising antibodies in patients treated with botulinum toxin type A for spasticity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12138306" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Clinical features of antibody-induced complete secondary failure of botulinum toxin therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22385408" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Clinical relevance of botulinum toxin immunogenicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15122715" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Clinical impact of antibody formation to botulinum toxin A in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8196686" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Development of resistance to botulinum toxin type A in patients with torticollis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9826987" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Botulinum toxin: chemistry, pharmacology, toxicity, and immunology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28385185" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Antibody responses to botulinum neurotoxin type A of toxin-treated spastic equinus children with cerebral palsy: A randomized clinical trial comparing two injection schedules.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9826983" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Traditional pharmacological treatments for spasticity. Part I: Local treatments.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15024330" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Clinical effects of botulinum toxin A and phenol block on gait in children with cerebral palsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29675072" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Phenol Versus Botulinum Toxin A Injection in Ambulatory Cerebral Palsy Spastic Diplegia: A Comparative Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18574347" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Safety profile of multilevel chemical denervation procedures using phenol or botulinum toxin or both in a pediatric population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15241761" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Combining botulinum toxin and phenol to manage spasticity in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17644918" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : The use of intrathecal baclofen pump implants in children and adolescents: safety and complications in 200 consecutive cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21635230" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Use of intrathecal baclofen therapy in ambulant children and adolescents with spasticity and dystonia of cerebral origin: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11034458" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Evidence of the effects of intrathecal baclofen for spastic and dystonic cerebral palsy. AACPDM Treatment Outcomes Committee Review Panel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29572808" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Readmission and complications within 30 days after intrathecal baclofen pump placement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30187921" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Effect of continuous intrathecal baclofen therapy in children: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18649160" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Intrathecal baclofen therapy for neurological disorders: a sound knowledge base but many challenges remain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19912148" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Continuous intrathecal baclofen therapy in children with cerebral palsy - when does improvement emerge?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21707598" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Controlled study of the effects of continuous intrathecal baclofen infusion in non-ambulant children with cerebral palsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8881981" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Baclofen in the treatment of cerebral palsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12593613" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Long-term intrathecal baclofen therapy for severe spasticity of cerebral origin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24577095" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Complications of intrathecal baclofen pumps in children: experience from a tertiary care center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24577095" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Complications of intrathecal baclofen pumps in children: experience from a tertiary care center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25670404" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Selective dorsal rhizotomy: an old treatment re-emerging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11811645" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Selective dorsal rhizotomy: meta-analysis of three randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9112967" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : A randomized clinical trial to compare selective posterior rhizotomy plus physiotherapy with physiotherapy alone in children with spastic diplegic cerebral palsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9593495" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Evaluation of selective dorsal rhizotomy for the reduction of spasticity in cerebral palsy: a randomized controlled tria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9593493" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Selective dorsal rhizotomy: efficacy and safety in an investigator-masked randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31047843" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Selective dorsal rhizotomy in ambulant children with cerebral palsy: an observational cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12186459" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Long-term functional outcome after selective posterior rhizotomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23713680" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Long-term functional benefits of selective dorsal rhizotomy for spastic cerebral palsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23557106" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Long-term effect of selective dorsal rhizotomy on gross motor function in ambulant children with spastic bilateral cerebral palsy, compared with reference centiles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22435543" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Motor function after selective dorsal rhizotomy: a 10-year practice-based follow-up study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25523506" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : A prospective cohort study investigating gross motor function, pain, and health-related quality of life 17 years after selective dorsal rhizotomy in cerebral palsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17475694" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Selective dorsal rhizotomy for children with cerebral palsy: the Oswestry experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34507281" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : More than 25 years after selective dorsal rhizotomy: physical status, quality of life, and levels of anxiety and depression in adults with cerebral palsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29116382" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Selective dorsal rhizotomy for the treatment of severe spastic cerebral palsy: efficacy and therapeutic durability in GMFCS grade IV and V children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26552383" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Selective dorsal rhizotomy as an alternative to intrathecal baclofen pump replacement in GMFCS grades 4 and 5 children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17805547" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Surgical treatment of spasticity in children: comparison of selective dorsal rhizotomy and intrathecal baclofen pump implantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29405267" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Pharmacological and neurosurgical interventions for managing dystonia in cerebral palsy: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33772789" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Pharmacological and neurosurgical interventions for individuals with cerebral palsy and dystonia: a systematic review update and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23408442" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Effects of deep brain stimulation in dyskinetic cerebral palsy: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19576854" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Bilateral pallidal deep brain stimulation for the treatment of patients with dystonia-choreoathetosis cerebral palsy: a prospective pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21491490" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Dystonia due to cerebral palsy responds to deep brain stimulation of the globus pallidus internus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2404019" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Management of the lower extremities in children who have cerebral palsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8458127" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Common gait abnormalities of the knee in cerebral palsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12004014" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Ankle and knee coupling in patients with spastic diplegia: effects of gastrocnemius-soleus lengthening.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16357554" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Effectiveness of upper and lower limb casting and orthoses in children with cerebral palsy: an overview of review articles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17880650" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : A systematic review of the effects of casting on equinus in children with cerebral palsy: an evidence report of the AACPDM.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26351821" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : A Critical Evaluation of the Updated Evidence for Casting for Equinus Deformity in Children with Cerebral Palsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33483965" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Intermittent serial casting for wrist flexion deformity in children with spastic cerebral palsy: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10344322" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Muscle-tendon surgery in diplegic cerebral palsy: functional and mechanical changes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25834076" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Tendon transfer surgery in upper-extremity cerebral palsy is more effective than botulinum toxin injections or regular, ongoing therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22111994" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Single-event multilevel surgery for children with cerebral palsy: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27755599" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : A Systematic Review of the Effects of Single-Event Multilevel Surgery on Gait Parameters in Children with Spastic Cerebral Palsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30073667" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Predictors affecting outcome after single-event multilevel surgery in children with cerebral palsy: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32011547" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Long-term Outcomes Following Multilevel Surgery in Cerebral Palsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12041941" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Management of hip disorders in patients with cerebral palsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17075096" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : A systematic review of the evidence for hip surveillance in children with cerebral palsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17075096" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : A systematic review of the evidence for hip surveillance in children with cerebral palsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26517269" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Effects of the standing program with hip abduction on hip acetabular development in children with spastic diplegia cerebral palsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33770798" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : Abducted Standing in Children With Cerebral Palsy: Effects on Hip Development After 7 Years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23147631" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : A comparison of hip dislocation rates and hip containment procedures after selective dorsal rhizotomy versus intrathecal baclofen pump insertion in nonambulatory cerebral palsy patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28574172" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : Prevention of hip displacement in children with cerebral palsy: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18171954" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : Does botulinum toxin a combined with bracing prevent hip displacement in children with cerebral palsy and "hips at risk"? A randomized, controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12188492" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : Hip surveillance in children with cerebral palsy. Impact on the surgical management of spastic hip disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25846730" id="rid145" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>146 : Australian hip surveillance guidelines for children with cerebral palsy: 5-year review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15686244" id="rid146" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>147 : Prevention of dislocation of the hip in children with cerebral palsy. The first ten years of a population-based prevention programme.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25371472" id="rid147" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>148 : Prevention of dislocation of the hip in children with cerebral palsy: 20-year results of a population-based prevention programme.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26057069" id="rid148" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>149 : Hip Reconstruction in Children With Unilateral Cerebral Palsy and Hip Dysplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6825328" id="rid149" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>150 : The untreated unstable hip in severe cerebral palsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36331502" id="rid150" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>151 : Efficacy of a Hip Brace for Hip Displacement in Children With Cerebral Palsy: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25788307" id="rid151" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>152 : Long-term results and outcome predictors in one-stage hip reconstruction in children with cerebral palsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28953164" id="rid152" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>153 : Bony reconstruction of hip in cerebral palsy children Gross Motor Function Classification System levels III to V: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35420583" id="rid153" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>154 : Can Over-containment Prevent Recurrence in Children With Cerebral Palsy and Hip Dysplasia Undergoing Hip Reconstruction?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30736784" id="rid154" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>155 : Hip pain in children with cerebral palsy: a population-based registry study of risk factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22336971" id="rid155" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>156 : Adductor surgery to prevent hip displacement in children with cerebral palsy: the predictive role of the Gross Motor Function Classification System.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22218299" id="rid156" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>157 : Scoliosis in a total population of children with cerebral palsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16757676" id="rid157" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>158 : Scoliosis in the child with cerebral palsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29705176" id="rid158" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>159 : Natural history of scoliosis in cerebral palsy and risk factors for progression of scoliosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32394323" id="rid159" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>160 : BMI change following spinal fusion for neuromuscular scoliosis surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18432437" id="rid160" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>161 : Conservative management of neuromuscular scoliosis: personal experience and review of literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29871529" id="rid161" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>162 : The effect of spinal bracing on sitting function in children with neuromuscular scoliosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27587527" id="rid162" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>163 : The use of magnetically-controlled growing rods to treat children with early-onset scoliosis: early radiological results in 19 children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30168755" id="rid163" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>164 : A six-year observational study of 31 children with early-onset scoliosis treated using magnetically controlled growing rods with a minimum follow-up of two years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29675673" id="rid164" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>165 : Systematic review of the complications associated with magnetically controlled growing rods for the treatment of early onset scoliosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31253410" id="rid165" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>166 : Parent-to-Parent Advice on Considering Spinal Fusion in Children with Neuromuscular Scoliosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31359785" id="rid166" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>167 : Pediatric complex care and surgery comanagement: Preparation for spinal fusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30143896" id="rid167" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>168 : Factors associated with surgical approach and outcomes in cerebral palsy scoliosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28262923" id="rid168" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>169 : Outcomes after scoliosis surgery for children with cerebral palsy: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26656322" id="rid169" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>170 : Does Spinal Fusion and Scoliosis Correction Improve Activity and Participation for Children With GMFCS level 4 and 5 Cerebral Palsy?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29613924" id="rid170" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>171 : Assessing the Risk-Benefit Ratio of Scoliosis Surgery in Cerebral Palsy: Surgery Is Worth It.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34296760" id="rid171" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>172 : Health-related quality of life and caregiver burden after hip reconstruction and spinal fusion in children with spastic cerebral palsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11508917" id="rid172" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>173 : Functional status of adults with cerebral palsy and implications for treatment of children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37679048" id="rid173" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>174 : Mortality and Causes of Death in Children With Cerebral Palsy With Scoliosis Treated With and Without Surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29749884" id="rid174" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>175 : Perioperative complications and risk factors in neuromuscular scoliosis surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34939971" id="rid175" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>176 : Mortality in Neuromuscular Early Onset Scoliosis Following Spinal Deformity Surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27807115" id="rid176" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>177 : Subclassification of GMFCS Level-5 Cerebral Palsy as a Predictor of Complications and Health-Related Quality of Life After Spinal Arthrodesis.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
